Document: Presentations/ffgg0257.zip/ffgg0257.pdf
Category: Presentations
Processed: 2025-06-12T12:03:53.888052
Method: pymupdf+enhanced_ocr
Text Length: 92925 chars
==================================================

=== Page 1 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
High level assessment of potential strategic options for Oxycontin
1 Only include Commercial and Part D accounts
2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza losing 60-70%% of the market share due to exclusion
2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza share grow by 10-40% YoY
3 Assuming  Oxycontin share drops by 65%  in 2020  and by 30% YoY in 2021 and 2022 due to exclusion, and Xtampza captures 75% of the share drop from Oxycontin
Key assumptions, 2022
3 year financial projection of net sales1 (after rebates and other GtN 
reductions)
Maintaining current access status could offer highest cumulative net 
sales in the longer term 
13
%2 
2%4
10
%3
Oxycontin 
Share
Oxycontin 
rebate
Commercial: 
50%
Medicare: 
70%
0%
Commercial: 
45%
Medicare: 
69%
(assuming 
2% increase 
YoY)
Oxycontin net sales1 ($M) 
Xtampza net sales1 ($M)
273
227
202
702
Secure 
exclusive 
position 
across all 
contracted 
accounts 
Maintain 
current 
access 
status with 
increasing 
rebates
Pull away 
rebates 
from all 
accounts
xx
3 year 
total
297
240
206
270
179
128
2020
21
2022
743
577
146
199
348
44
55
47
66
65
69
120
115
113
21
2020
2022
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 1 Image 1 (OCR) ===
—

=== Page 1 Image 2 (OCR) ===
oe

=== Page 1 Image 3 (OCR) ===
a

=== Page 1 Image 4 (OCR) ===
Qunoue).

=== Page 1 Image 6 (OCR) ===
guaoue)

=== Page 1 Image 7 (OCR) ===
a

=== Page 1 Image 8 (OCR) ===
uaoue).

=== Page 1 Image 9 (OCR) ===
euaoue).

=== Page 1 Image 10 (OCR) ===
a

=== Page 1 Image 11 (OCR) ===
—

=== Page 1 Image 12 (OCR) ===
oe

=== Page 1 Image 13 (OCR) ===
a

=== Page 1 Image 14 (OCR) ===
Qunoue).

=== Page 1 Image 16 (OCR) ===
guaoue)

=== Page 1 Image 17 (OCR) ===
a

=== Page 1 Image 18 (OCR) ===
uaoue).

=== Page 1 Image 19 (OCR) ===
euaoue).

=== Page 1 Image 20 (OCR) ===
a

=== Page 1 Image 21 (OCR) ===
—

=== Page 1 Image 22 (OCR) ===
oe

=== Page 1 Image 23 (OCR) ===
a

=== Page 1 Image 24 (OCR) ===
Qunoue).

=== Page 1 Image 26 (OCR) ===
guaoue)

=== Page 1 Image 27 (OCR) ===
a

=== Page 1 Image 28 (OCR) ===
uaoue).

=== Page 1 Image 29 (OCR) ===
euaoue).

=== Page 1 Image 30 (OCR) ===
a

=== Page 1 Image 31 (OCR) ===
—

=== Page 1 Image 32 (OCR) ===
oe

=== Page 1 Image 33 (OCR) ===
a

=== Page 1 Image 34 (OCR) ===
Qunoue).

=== Page 1 Image 36 (OCR) ===
guaoue)

=== Page 1 Image 37 (OCR) ===
a

=== Page 1 Image 38 (OCR) ===
uaoue).

=== Page 1 Image 39 (OCR) ===
euaoue).

=== Page 1 Image 40 (OCR) ===
a

=== Page 1 Image 41 (OCR) ===
—

=== Page 1 Image 42 (OCR) ===
oe

=== Page 1 Image 43 (OCR) ===
a

=== Page 1 Image 44 (OCR) ===
Qunoue).

=== Page 1 Image 46 (OCR) ===
guaoue)

=== Page 1 Image 47 (OCR) ===
a

=== Page 1 Image 48 (OCR) ===
uaoue).

=== Page 1 Image 49 (OCR) ===
euaoue).

=== Page 1 Image 50 (OCR) ===
a

=== Page 1 Image 51 (OCR) ===
—

=== Page 1 Image 52 (OCR) ===
oe

=== Page 1 Image 53 (OCR) ===
a

=== Page 1 Image 54 (OCR) ===
Qunoue).

=== Page 1 Image 56 (OCR) ===
guaoue)

=== Page 1 Image 57 (OCR) ===
a

=== Page 1 Image 58 (OCR) ===
uaoue).

=== Page 1 Image 59 (OCR) ===
euaoue).

=== Page 1 Image 60 (OCR) ===
a

=== Page 1 Image 61 (OCR) ===
—

=== Page 1 Image 62 (OCR) ===
oe

=== Page 1 Image 63 (OCR) ===
a

=== Page 1 Image 64 (OCR) ===
Qunoue).

=== Page 1 Image 66 (OCR) ===
guaoue)

=== Page 1 Image 67 (OCR) ===
a

=== Page 1 Image 68 (OCR) ===
uaoue).

=== Page 1 Image 69 (OCR) ===
euaoue).

=== Page 1 Image 70 (OCR) ===
a

=== Page 2 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
• OxyContin and Hysingla ER maintain strong access on Envision’s formularies, with OxyContin maintaining preferred status on 66% of 
lives 
• Collegium’s products are nearly completely excluded on all Envision formularies
1 Defined as percentage of lives that are either preferred or covered (including PA/ST)
Current access status: OxyContin is preferred for 66% of lives on Envision Part D formularies
2
SOURCE: MMIT
25
466
203
27
51
Not 
Covered
Preferre
d
Covered 
(PA/ST)
Not 
Covered
Not 
Covered
Not 
Covered
Covered 
(PA/ST)
Preferre
d
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Privileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal 
and regulatory review before they can be considered final. These materials are confidential and proprietary.
MCS Classicare II
HealthSun MediMax 
Preferre
d
Not 
Covered
Preferre
d
Not 
Covered
EnvisionRxPlus PDP
Covered
Not 
Covered
Not 
Covered
Covered 
(PA/ST)
74%
1%
92%
0%
65%
EnvisionRxPlus Hybrid PDP
HealthTeam Advantage Plan
Covered 
(PA/ST)
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Lives, K
Overall formulary 
status
Lives, 
%
Hysingl
a ER
Xtampz
a ER
OxyCo
ntin
Nucynt
a ER
Zohydr
o ER
Largest formulary
Purdue 
preferred, 
Zohydro covered
Only Oxycontin 
covered
Purdue portfolio 
exclusive 
coverage 
Only branded 
hydrocodone 
coverage
Only Hysingla ER 
covered
Overall covered 
lives %1
59
%
26
%
7%
3%
3%
Oxycontin Covered
Not covered
Coverage status of leading ERO brands, 
Nov 2018
ENVISION
789
Total
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 2 Image 1 (OCR) ===
—

=== Page 2 Image 2 (OCR) ===
oe

=== Page 2 Image 3 (OCR) ===
a

=== Page 2 Image 4 (OCR) ===
Qunoue).

=== Page 2 Image 6 (OCR) ===
guaoue)

=== Page 2 Image 7 (OCR) ===
a

=== Page 2 Image 8 (OCR) ===
uaoue).

=== Page 2 Image 9 (OCR) ===
euaoue).

=== Page 2 Image 10 (OCR) ===
a

=== Page 2 Image 11 (OCR) ===
—

=== Page 2 Image 12 (OCR) ===
oe

=== Page 2 Image 13 (OCR) ===
a

=== Page 2 Image 14 (OCR) ===
Qunoue).

=== Page 2 Image 16 (OCR) ===
guaoue)

=== Page 2 Image 17 (OCR) ===
a

=== Page 2 Image 18 (OCR) ===
uaoue).

=== Page 2 Image 19 (OCR) ===
euaoue).

=== Page 2 Image 20 (OCR) ===
a

=== Page 2 Image 21 (OCR) ===
—

=== Page 2 Image 22 (OCR) ===
oe

=== Page 2 Image 23 (OCR) ===
a

=== Page 2 Image 24 (OCR) ===
Qunoue).

=== Page 2 Image 26 (OCR) ===
guaoue)

=== Page 2 Image 27 (OCR) ===
a

=== Page 2 Image 28 (OCR) ===
uaoue).

=== Page 2 Image 29 (OCR) ===
euaoue).

=== Page 2 Image 30 (OCR) ===
a

=== Page 2 Image 31 (OCR) ===
—

=== Page 2 Image 32 (OCR) ===
oe

=== Page 2 Image 33 (OCR) ===
a

=== Page 2 Image 34 (OCR) ===
Qunoue).

=== Page 2 Image 36 (OCR) ===
guaoue)

=== Page 2 Image 37 (OCR) ===
a

=== Page 2 Image 38 (OCR) ===
uaoue).

=== Page 2 Image 39 (OCR) ===
euaoue).

=== Page 2 Image 40 (OCR) ===
a

=== Page 2 Image 41 (OCR) ===
—

=== Page 2 Image 42 (OCR) ===
oe

=== Page 2 Image 43 (OCR) ===
a

=== Page 2 Image 44 (OCR) ===
Qunoue).

=== Page 2 Image 46 (OCR) ===
guaoue)

=== Page 2 Image 47 (OCR) ===
a

=== Page 2 Image 48 (OCR) ===
uaoue).

=== Page 2 Image 49 (OCR) ===
euaoue).

=== Page 2 Image 50 (OCR) ===
a

=== Page 2 Image 51 (OCR) ===
—

=== Page 2 Image 52 (OCR) ===
oe

=== Page 2 Image 53 (OCR) ===
a

=== Page 2 Image 54 (OCR) ===
Qunoue).

=== Page 2 Image 56 (OCR) ===
guaoue)

=== Page 2 Image 57 (OCR) ===
a

=== Page 2 Image 58 (OCR) ===
uaoue).

=== Page 2 Image 59 (OCR) ===
euaoue).

=== Page 2 Image 60 (OCR) ===
a

=== Page 2 Image 61 (OCR) ===
—

=== Page 2 Image 62 (OCR) ===
oe

=== Page 2 Image 63 (OCR) ===
a

=== Page 2 Image 64 (OCR) ===
Qunoue).

=== Page 2 Image 66 (OCR) ===
guaoue)

=== Page 2 Image 67 (OCR) ===
a

=== Page 2 Image 68 (OCR) ===
uaoue).

=== Page 2 Image 69 (OCR) ===
euaoue).

=== Page 2 Image 70 (OCR) ===
a

=== Page 3 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We defined potential 2020 access scenarios for Oxycontin vs. Xtampza
2020 Share shift assumptions under different scenarios, 2020 Q4 
2020 access 
scenarios
Continue current 
access status as  
exclusive preferred 
oxycodone ER
1
Both Oxycontin and 
Xtampza preferred 
2
Xtampza preferred, 
Oxycontin non-
preferred
3
Xtampza replaces 
Oxycontin as 
exclusive preferred 
with 
grandfathering
4
Oxycontin Excluded 
without 
grandfathering
5
5
1
22
6
15
8
7
8
3
12
9
5
4
11
22
8
9
22
6
8
6
9
8
9
7
6
9
3
10
22
22
22
22
22
22
7
Oxycontin
Xtampza
Other brands
Share by products (exit share) 
Share shift vs. 
status quo 
Low
Hig
h
Low
Hig
h
Low
Hig
h
Low
Hig
h
20%
40%
30%
68%
50%
70%
60%
80%
0%
PRIME
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 3 Image 1 (OCR) ===
—

=== Page 3 Image 2 (OCR) ===
oe

=== Page 3 Image 3 (OCR) ===
a

=== Page 3 Image 4 (OCR) ===
Qunoue).

=== Page 3 Image 6 (OCR) ===
guaoue)

=== Page 3 Image 7 (OCR) ===
a

=== Page 3 Image 8 (OCR) ===
uaoue).

=== Page 3 Image 9 (OCR) ===
euaoue).

=== Page 3 Image 10 (OCR) ===
a

=== Page 3 Image 11 (OCR) ===
—

=== Page 3 Image 12 (OCR) ===
oe

=== Page 3 Image 13 (OCR) ===
a

=== Page 3 Image 14 (OCR) ===
Qunoue).

=== Page 3 Image 16 (OCR) ===
guaoue)

=== Page 3 Image 17 (OCR) ===
a

=== Page 3 Image 18 (OCR) ===
uaoue).

=== Page 3 Image 19 (OCR) ===
euaoue).

=== Page 3 Image 20 (OCR) ===
a

=== Page 3 Image 21 (OCR) ===
—

=== Page 3 Image 22 (OCR) ===
oe

=== Page 3 Image 23 (OCR) ===
a

=== Page 3 Image 24 (OCR) ===
Qunoue).

=== Page 3 Image 26 (OCR) ===
guaoue)

=== Page 3 Image 27 (OCR) ===
a

=== Page 3 Image 28 (OCR) ===
uaoue).

=== Page 3 Image 29 (OCR) ===
euaoue).

=== Page 3 Image 30 (OCR) ===
a

=== Page 3 Image 31 (OCR) ===
—

=== Page 3 Image 32 (OCR) ===
oe

=== Page 3 Image 33 (OCR) ===
a

=== Page 3 Image 34 (OCR) ===
Qunoue).

=== Page 3 Image 36 (OCR) ===
guaoue)

=== Page 3 Image 37 (OCR) ===
a

=== Page 3 Image 38 (OCR) ===
uaoue).

=== Page 3 Image 39 (OCR) ===
euaoue).

=== Page 3 Image 40 (OCR) ===
a

=== Page 3 Image 41 (OCR) ===
—

=== Page 3 Image 42 (OCR) ===
oe

=== Page 3 Image 43 (OCR) ===
a

=== Page 3 Image 44 (OCR) ===
Qunoue).

=== Page 3 Image 46 (OCR) ===
guaoue)

=== Page 3 Image 47 (OCR) ===
a

=== Page 3 Image 48 (OCR) ===
uaoue).

=== Page 3 Image 49 (OCR) ===
euaoue).

=== Page 3 Image 50 (OCR) ===
a

=== Page 3 Image 51 (OCR) ===
—

=== Page 3 Image 52 (OCR) ===
oe

=== Page 3 Image 53 (OCR) ===
a

=== Page 3 Image 54 (OCR) ===
Qunoue).

=== Page 3 Image 56 (OCR) ===
guaoue)

=== Page 3 Image 57 (OCR) ===
a

=== Page 3 Image 58 (OCR) ===
uaoue).

=== Page 3 Image 59 (OCR) ===
euaoue).

=== Page 3 Image 60 (OCR) ===
a

=== Page 3 Image 61 (OCR) ===
—

=== Page 3 Image 62 (OCR) ===
oe

=== Page 3 Image 63 (OCR) ===
a

=== Page 3 Image 64 (OCR) ===
Qunoue).

=== Page 3 Image 66 (OCR) ===
guaoue)

=== Page 3 Image 67 (OCR) ===
a

=== Page 3 Image 68 (OCR) ===
uaoue).

=== Page 3 Image 69 (OCR) ===
euaoue).

=== Page 3 Image 70 (OCR) ===
a

=== Page 4 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios
1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”
2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  
10.8
11.0
11.5
13.2
7.2
6.2
11.2
7.9
10.2
6.6
2020 access 
scenarios
Both 
Oxycontin and 
Xtampza 
preferred 
Xtampza 
preferred, 
Oxycontin 
non-preferred
Continue 
current access 
status as  
exclusive 
preferred
oxycodone ER
Xtampza 
replacing 
Oxycontin as 
exclusive 
preferred with 
grandfathering
Oxycontin 
Excluded 
without 
grandfatherin
g
Xtampza net 
sales ($M)
1
2
3
4
0%
40%
50%
70%
70%
Assumed 
Xtampza 
rebate
Implication on Oxycontin bidding strategy
s to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. 
2.1
3.2
0.8
2.9
1.6
1.1
1.8
1.6
Share by 
product, 2020 
Q4
Other brand 
net sales ($M)
5
3
22
9
8
7
12
22
6
4
5
9
6
8
11
9
7
6
8
22
8
5
9
8
9
7
10
3
22
22
22
22
22
8.0
7.3
7.7
8.8
8.4
8.8
9.2
9.6
Oxycontin
Other brands
Xtampza
PRIME
0.7
22
6
1
15
6.5
Low
High
Low
High
Low
High
Low
High
Low
High
Shar
e 
shift
Break-
even 
rebate2 
37%
48%
32%
37%
N/A
30%
44%
60%
45%
Net sales at min 
rebate ($M)
42%
Rebate rate to keep 
Prime whole1 
30%
44%
27%
40%
N/A
24%
36%
32%
Theoretic
al – 
unlikely 
able to 
lower 
current 
rate 
(40%)
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 4 Image 1 (OCR) ===
—

=== Page 4 Image 2 (OCR) ===
oe

=== Page 4 Image 3 (OCR) ===
a

=== Page 4 Image 4 (OCR) ===
Qunoue).

=== Page 4 Image 6 (OCR) ===
guaoue)

=== Page 4 Image 7 (OCR) ===
a

=== Page 4 Image 8 (OCR) ===
uaoue).

=== Page 4 Image 9 (OCR) ===
euaoue).

=== Page 4 Image 10 (OCR) ===
a

=== Page 4 Image 11 (OCR) ===
—

=== Page 4 Image 12 (OCR) ===
oe

=== Page 4 Image 13 (OCR) ===
a

=== Page 4 Image 14 (OCR) ===
Qunoue).

=== Page 4 Image 16 (OCR) ===
guaoue)

=== Page 4 Image 17 (OCR) ===
a

=== Page 4 Image 18 (OCR) ===
uaoue).

=== Page 4 Image 19 (OCR) ===
euaoue).

=== Page 4 Image 20 (OCR) ===
a

=== Page 4 Image 21 (OCR) ===
—

=== Page 4 Image 22 (OCR) ===
oe

=== Page 4 Image 23 (OCR) ===
a

=== Page 4 Image 24 (OCR) ===
Qunoue).

=== Page 4 Image 26 (OCR) ===
guaoue)

=== Page 4 Image 27 (OCR) ===
a

=== Page 4 Image 28 (OCR) ===
uaoue).

=== Page 4 Image 29 (OCR) ===
euaoue).

=== Page 4 Image 30 (OCR) ===
a

=== Page 4 Image 31 (OCR) ===
—

=== Page 4 Image 32 (OCR) ===
oe

=== Page 4 Image 33 (OCR) ===
a

=== Page 4 Image 34 (OCR) ===
Qunoue).

=== Page 4 Image 36 (OCR) ===
guaoue)

=== Page 4 Image 37 (OCR) ===
a

=== Page 4 Image 38 (OCR) ===
uaoue).

=== Page 4 Image 39 (OCR) ===
euaoue).

=== Page 4 Image 40 (OCR) ===
a

=== Page 4 Image 41 (OCR) ===
—

=== Page 4 Image 42 (OCR) ===
oe

=== Page 4 Image 43 (OCR) ===
a

=== Page 4 Image 44 (OCR) ===
Qunoue).

=== Page 4 Image 46 (OCR) ===
guaoue)

=== Page 4 Image 47 (OCR) ===
a

=== Page 4 Image 48 (OCR) ===
uaoue).

=== Page 4 Image 49 (OCR) ===
euaoue).

=== Page 4 Image 50 (OCR) ===
a

=== Page 4 Image 51 (OCR) ===
—

=== Page 4 Image 52 (OCR) ===
oe

=== Page 4 Image 53 (OCR) ===
a

=== Page 4 Image 54 (OCR) ===
Qunoue).

=== Page 4 Image 56 (OCR) ===
guaoue)

=== Page 4 Image 57 (OCR) ===
a

=== Page 4 Image 58 (OCR) ===
uaoue).

=== Page 4 Image 59 (OCR) ===
euaoue).

=== Page 4 Image 60 (OCR) ===
a

=== Page 4 Image 61 (OCR) ===
—

=== Page 4 Image 62 (OCR) ===
oe

=== Page 4 Image 63 (OCR) ===
a

=== Page 4 Image 64 (OCR) ===
Qunoue).

=== Page 4 Image 66 (OCR) ===
guaoue)

=== Page 4 Image 67 (OCR) ===
a

=== Page 4 Image 68 (OCR) ===
uaoue).

=== Page 4 Image 69 (OCR) ===
euaoue).

=== Page 4 Image 70 (OCR) ===
a

=== Page 5 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Long term view: 2020-2022 financial impact under different access scenarios
1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”
2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  
20.3
17.3
10.2
14.5
16.0
19.4
12.5
19.2
Access scenarios
Both Oxycontin 
and Xtampza 
preferred 
Xtampza 
preferred, 
Oxycontin non-
preferred
Continue current 
access status as  
exclusive preferred
oxycodone ER
Xtampza replacing 
Oxycontin as 
exclusive preferred 
with grandfathering
60%
50%
43%
5%
0%
Oxycontin 
Excluded without 
grandfathering
2020
1
2
3
4
Assumed 
Oxycontin 
rebate, 2022
3 year total ($M)
Share 
shift
Maintaining  current access status could maximize net sales in the longer term as well, assuming reasonable increase in rebate rate
6.6
10.6
9.6
8.7
10.2
7.5
10.6
11.1
Share by 
product, 2022 
Q4
2021
5
20
3
5
20
4
8
20
9
7
10
7
8
8
5
9
7
9
9
9
2
9
20
10
20
1
20
9
1
9
1
20
20
3.4
6.0
2.6
5.6
6.4
4.8
3.4
5.1
Oxycontin
Other brands
Xtampza
PRIME
10.8
0 6
13
20
7.3
Low
High
Low
High
Low
High
Low
High
Low
High
Oxycontin net sales ($M)
2022
4.3
2.8
3.3
1.5
2.5
1.6
2.4
1.0
2.0
22.4
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 5 Image 1 (OCR) ===
—

=== Page 5 Image 2 (OCR) ===
oe

=== Page 5 Image 3 (OCR) ===
a

=== Page 5 Image 4 (OCR) ===
Qunoue).

=== Page 5 Image 6 (OCR) ===
guaoue)

=== Page 5 Image 7 (OCR) ===
a

=== Page 5 Image 8 (OCR) ===
uaoue).

=== Page 5 Image 9 (OCR) ===
euaoue).

=== Page 5 Image 10 (OCR) ===
a

=== Page 5 Image 11 (OCR) ===
—

=== Page 5 Image 12 (OCR) ===
oe

=== Page 5 Image 13 (OCR) ===
a

=== Page 5 Image 14 (OCR) ===
Qunoue).

=== Page 5 Image 16 (OCR) ===
guaoue)

=== Page 5 Image 17 (OCR) ===
a

=== Page 5 Image 18 (OCR) ===
uaoue).

=== Page 5 Image 19 (OCR) ===
euaoue).

=== Page 5 Image 20 (OCR) ===
a

=== Page 5 Image 21 (OCR) ===
—

=== Page 5 Image 22 (OCR) ===
oe

=== Page 5 Image 23 (OCR) ===
a

=== Page 5 Image 24 (OCR) ===
Qunoue).

=== Page 5 Image 26 (OCR) ===
guaoue)

=== Page 5 Image 27 (OCR) ===
a

=== Page 5 Image 28 (OCR) ===
uaoue).

=== Page 5 Image 29 (OCR) ===
euaoue).

=== Page 5 Image 30 (OCR) ===
a

=== Page 5 Image 31 (OCR) ===
—

=== Page 5 Image 32 (OCR) ===
oe

=== Page 5 Image 33 (OCR) ===
a

=== Page 5 Image 34 (OCR) ===
Qunoue).

=== Page 5 Image 36 (OCR) ===
guaoue)

=== Page 5 Image 37 (OCR) ===
a

=== Page 5 Image 38 (OCR) ===
uaoue).

=== Page 5 Image 39 (OCR) ===
euaoue).

=== Page 5 Image 40 (OCR) ===
a

=== Page 5 Image 41 (OCR) ===
—

=== Page 5 Image 42 (OCR) ===
oe

=== Page 5 Image 43 (OCR) ===
a

=== Page 5 Image 44 (OCR) ===
Qunoue).

=== Page 5 Image 46 (OCR) ===
guaoue)

=== Page 5 Image 47 (OCR) ===
a

=== Page 5 Image 48 (OCR) ===
uaoue).

=== Page 5 Image 49 (OCR) ===
euaoue).

=== Page 5 Image 50 (OCR) ===
a

=== Page 5 Image 51 (OCR) ===
—

=== Page 5 Image 52 (OCR) ===
oe

=== Page 5 Image 53 (OCR) ===
a

=== Page 5 Image 54 (OCR) ===
Qunoue).

=== Page 5 Image 56 (OCR) ===
guaoue)

=== Page 5 Image 57 (OCR) ===
a

=== Page 5 Image 58 (OCR) ===
uaoue).

=== Page 5 Image 59 (OCR) ===
euaoue).

=== Page 5 Image 60 (OCR) ===
a

=== Page 5 Image 61 (OCR) ===
—

=== Page 5 Image 62 (OCR) ===
oe

=== Page 5 Image 63 (OCR) ===
a

=== Page 5 Image 64 (OCR) ===
Qunoue).

=== Page 5 Image 66 (OCR) ===
guaoue)

=== Page 5 Image 67 (OCR) ===
a

=== Page 5 Image 68 (OCR) ===
uaoue).

=== Page 5 Image 69 (OCR) ===
euaoue).

=== Page 5 Image 70 (OCR) ===
a

=== Page 6 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
BACKUP
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 6 Image 1 (OCR) ===
—

=== Page 6 Image 2 (OCR) ===
oe

=== Page 6 Image 3 (OCR) ===
a

=== Page 6 Image 4 (OCR) ===
Qunoue).

=== Page 6 Image 6 (OCR) ===
guaoue)

=== Page 6 Image 7 (OCR) ===
a

=== Page 6 Image 8 (OCR) ===
uaoue).

=== Page 6 Image 9 (OCR) ===
euaoue).

=== Page 6 Image 10 (OCR) ===
a

=== Page 6 Image 11 (OCR) ===
—

=== Page 6 Image 12 (OCR) ===
oe

=== Page 6 Image 13 (OCR) ===
a

=== Page 6 Image 14 (OCR) ===
Qunoue).

=== Page 6 Image 16 (OCR) ===
guaoue)

=== Page 6 Image 17 (OCR) ===
a

=== Page 6 Image 18 (OCR) ===
uaoue).

=== Page 6 Image 19 (OCR) ===
euaoue).

=== Page 6 Image 20 (OCR) ===
a

=== Page 6 Image 21 (OCR) ===
—

=== Page 6 Image 22 (OCR) ===
oe

=== Page 6 Image 23 (OCR) ===
a

=== Page 6 Image 24 (OCR) ===
Qunoue).

=== Page 6 Image 26 (OCR) ===
guaoue)

=== Page 6 Image 27 (OCR) ===
a

=== Page 6 Image 28 (OCR) ===
uaoue).

=== Page 6 Image 29 (OCR) ===
euaoue).

=== Page 6 Image 30 (OCR) ===
a

=== Page 6 Image 31 (OCR) ===
—

=== Page 6 Image 32 (OCR) ===
oe

=== Page 6 Image 33 (OCR) ===
a

=== Page 6 Image 34 (OCR) ===
Qunoue).

=== Page 6 Image 36 (OCR) ===
guaoue)

=== Page 6 Image 37 (OCR) ===
a

=== Page 6 Image 38 (OCR) ===
uaoue).

=== Page 6 Image 39 (OCR) ===
euaoue).

=== Page 6 Image 40 (OCR) ===
a

=== Page 6 Image 41 (OCR) ===
—

=== Page 6 Image 42 (OCR) ===
oe

=== Page 6 Image 43 (OCR) ===
a

=== Page 6 Image 44 (OCR) ===
Qunoue).

=== Page 6 Image 46 (OCR) ===
guaoue)

=== Page 6 Image 47 (OCR) ===
a

=== Page 6 Image 48 (OCR) ===
uaoue).

=== Page 6 Image 49 (OCR) ===
euaoue).

=== Page 6 Image 50 (OCR) ===
a

=== Page 6 Image 51 (OCR) ===
—

=== Page 6 Image 52 (OCR) ===
oe

=== Page 6 Image 53 (OCR) ===
a

=== Page 6 Image 54 (OCR) ===
Qunoue).

=== Page 6 Image 56 (OCR) ===
guaoue)

=== Page 6 Image 57 (OCR) ===
a

=== Page 6 Image 58 (OCR) ===
uaoue).

=== Page 6 Image 59 (OCR) ===
euaoue).

=== Page 6 Image 60 (OCR) ===
a

=== Page 6 Image 61 (OCR) ===
—

=== Page 6 Image 62 (OCR) ===
oe

=== Page 6 Image 63 (OCR) ===
a

=== Page 6 Image 64 (OCR) ===
Qunoue).

=== Page 6 Image 66 (OCR) ===
guaoue)

=== Page 6 Image 67 (OCR) ===
a

=== Page 6 Image 68 (OCR) ===
uaoue).

=== Page 6 Image 69 (OCR) ===
euaoue).

=== Page 6 Image 70 (OCR) ===
a

=== Page 7 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Assessment of current performance of Collegium
Collegium strategy going forward: key ingoing assumptions
• 2 product portfolio exclusively in pain management therapeutic area, with 
R&D pipeline all early life (Ph II or earlier) and concentrated in pain 
management1
• Facing “finite” market for its current portfolio, driven by:
– Overall U.S. ERO market continuing to decline (-15% YoY decline2 until 
2020)
– Likely genericization of extended-release oxycodone with abuse-deterrent 
formulations, leading to a market shift away from branded opioids
• Product portfolio is facing challenges
– Xtampza ER (oxycodone): $50.9M sales in Q1-Q3 20182
• Competing with an established market leader in a highly genericized class
– Nucynta (tapentadol): $156M sales in Q1-Q3 20182
• Slow launch since acquisition and experiencing share loss (-4% TRx from 
Q2-Q3 ’18)
• Collegium responsible for minimum $135M/yr royalty payment for first 4 
years of licensing regardless of product performance
• Collegium continues to invest in salesforce reps (~150) calling on specialists 
(~10,700) for both products
• Overall, Collegium is unprofitable ($31M loss from operations Q1-Q3 2018)
– ($0.50) EPS for Q3 ’18, missing Thomson Reuters’ consensus estimate of 
($0 36)
1 Collegium has one preclinical ADHD molecule
2 Based on Purdue internal projection
3 Based on Collegium 2018 Q3 10-Q 
• Given finite market 
outlook and Collegium’s 
need to quickly return to 
profitability, there are 2 
potential strategic 
choices:
– Reduce cost by 
downsizing salesforces, 
which could potentially 
lower expected sales 
growth
– Augment volume with 
aggressive bidding 
SOURCE: SEC filings, Internal research
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 7 Image 1 (OCR) ===
—

=== Page 7 Image 2 (OCR) ===
oe

=== Page 7 Image 3 (OCR) ===
a

=== Page 7 Image 4 (OCR) ===
Qunoue).

=== Page 7 Image 6 (OCR) ===
guaoue)

=== Page 7 Image 7 (OCR) ===
a

=== Page 7 Image 8 (OCR) ===
uaoue).

=== Page 7 Image 9 (OCR) ===
euaoue).

=== Page 7 Image 10 (OCR) ===
a

=== Page 7 Image 11 (OCR) ===
—

=== Page 7 Image 12 (OCR) ===
oe

=== Page 7 Image 13 (OCR) ===
a

=== Page 7 Image 14 (OCR) ===
Qunoue).

=== Page 7 Image 16 (OCR) ===
guaoue)

=== Page 7 Image 17 (OCR) ===
a

=== Page 7 Image 18 (OCR) ===
uaoue).

=== Page 7 Image 19 (OCR) ===
euaoue).

=== Page 7 Image 20 (OCR) ===
a

=== Page 7 Image 21 (OCR) ===
—

=== Page 7 Image 22 (OCR) ===
oe

=== Page 7 Image 23 (OCR) ===
a

=== Page 7 Image 24 (OCR) ===
Qunoue).

=== Page 7 Image 26 (OCR) ===
guaoue)

=== Page 7 Image 27 (OCR) ===
a

=== Page 7 Image 28 (OCR) ===
uaoue).

=== Page 7 Image 29 (OCR) ===
euaoue).

=== Page 7 Image 30 (OCR) ===
a

=== Page 7 Image 31 (OCR) ===
—

=== Page 7 Image 32 (OCR) ===
oe

=== Page 7 Image 33 (OCR) ===
a

=== Page 7 Image 34 (OCR) ===
Qunoue).

=== Page 7 Image 36 (OCR) ===
guaoue)

=== Page 7 Image 37 (OCR) ===
a

=== Page 7 Image 38 (OCR) ===
uaoue).

=== Page 7 Image 39 (OCR) ===
euaoue).

=== Page 7 Image 40 (OCR) ===
a

=== Page 7 Image 41 (OCR) ===
—

=== Page 7 Image 42 (OCR) ===
oe

=== Page 7 Image 43 (OCR) ===
a

=== Page 7 Image 44 (OCR) ===
Qunoue).

=== Page 7 Image 46 (OCR) ===
guaoue)

=== Page 7 Image 47 (OCR) ===
a

=== Page 7 Image 48 (OCR) ===
uaoue).

=== Page 7 Image 49 (OCR) ===
euaoue).

=== Page 7 Image 50 (OCR) ===
a

=== Page 7 Image 51 (OCR) ===
—

=== Page 7 Image 52 (OCR) ===
oe

=== Page 7 Image 53 (OCR) ===
a

=== Page 7 Image 54 (OCR) ===
Qunoue).

=== Page 7 Image 56 (OCR) ===
guaoue)

=== Page 7 Image 57 (OCR) ===
a

=== Page 7 Image 58 (OCR) ===
uaoue).

=== Page 7 Image 59 (OCR) ===
euaoue).

=== Page 7 Image 60 (OCR) ===
a

=== Page 7 Image 61 (OCR) ===
—

=== Page 7 Image 62 (OCR) ===
oe

=== Page 7 Image 63 (OCR) ===
a

=== Page 7 Image 64 (OCR) ===
Qunoue).

=== Page 7 Image 66 (OCR) ===
guaoue)

=== Page 7 Image 67 (OCR) ===
a

=== Page 7 Image 68 (OCR) ===
uaoue).

=== Page 7 Image 69 (OCR) ===
euaoue).

=== Page 7 Image 70 (OCR) ===
a

=== Page 8 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Current view of Collegium profitability
452
217
174
172
63
70
182
80
-32
Gross sales
Loss 
from 
operati
ons
Rebates
Other 
GTN 
reductio
ns
Net sales
9
COGS
R&D
SG&A
24
252
626
88
287
128
32
Xtampza
Nucynta
Overall 
Revenue and GTN 
reductions
Costs and operating 
expenses
2018 financial performance (estimation) 
($ Millions)
• Cash at the end of 
Q3 2018:  ~$140 
Mn
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 8 Image 1 (OCR) ===
—

=== Page 8 Image 2 (OCR) ===
oe

=== Page 8 Image 3 (OCR) ===
a

=== Page 8 Image 4 (OCR) ===
Qunoue).

=== Page 8 Image 6 (OCR) ===
guaoue)

=== Page 8 Image 7 (OCR) ===
a

=== Page 8 Image 8 (OCR) ===
uaoue).

=== Page 8 Image 9 (OCR) ===
euaoue).

=== Page 8 Image 10 (OCR) ===
a

=== Page 8 Image 11 (OCR) ===
—

=== Page 8 Image 12 (OCR) ===
oe

=== Page 8 Image 13 (OCR) ===
a

=== Page 8 Image 14 (OCR) ===
Qunoue).

=== Page 8 Image 16 (OCR) ===
guaoue)

=== Page 8 Image 17 (OCR) ===
a

=== Page 8 Image 18 (OCR) ===
uaoue).

=== Page 8 Image 19 (OCR) ===
euaoue).

=== Page 8 Image 20 (OCR) ===
a

=== Page 8 Image 21 (OCR) ===
—

=== Page 8 Image 22 (OCR) ===
oe

=== Page 8 Image 23 (OCR) ===
a

=== Page 8 Image 24 (OCR) ===
Qunoue).

=== Page 8 Image 26 (OCR) ===
guaoue)

=== Page 8 Image 27 (OCR) ===
a

=== Page 8 Image 28 (OCR) ===
uaoue).

=== Page 8 Image 29 (OCR) ===
euaoue).

=== Page 8 Image 30 (OCR) ===
a

=== Page 8 Image 31 (OCR) ===
—

=== Page 8 Image 32 (OCR) ===
oe

=== Page 8 Image 33 (OCR) ===
a

=== Page 8 Image 34 (OCR) ===
Qunoue).

=== Page 8 Image 36 (OCR) ===
guaoue)

=== Page 8 Image 37 (OCR) ===
a

=== Page 8 Image 38 (OCR) ===
uaoue).

=== Page 8 Image 39 (OCR) ===
euaoue).

=== Page 8 Image 40 (OCR) ===
a

=== Page 8 Image 41 (OCR) ===
—

=== Page 8 Image 42 (OCR) ===
oe

=== Page 8 Image 43 (OCR) ===
a

=== Page 8 Image 44 (OCR) ===
Qunoue).

=== Page 8 Image 46 (OCR) ===
guaoue)

=== Page 8 Image 47 (OCR) ===
a

=== Page 8 Image 48 (OCR) ===
uaoue).

=== Page 8 Image 49 (OCR) ===
euaoue).

=== Page 8 Image 50 (OCR) ===
a

=== Page 8 Image 51 (OCR) ===
—

=== Page 8 Image 52 (OCR) ===
oe

=== Page 8 Image 53 (OCR) ===
a

=== Page 8 Image 54 (OCR) ===
Qunoue).

=== Page 8 Image 56 (OCR) ===
guaoue)

=== Page 8 Image 57 (OCR) ===
a

=== Page 8 Image 58 (OCR) ===
uaoue).

=== Page 8 Image 59 (OCR) ===
euaoue).

=== Page 8 Image 60 (OCR) ===
a

=== Page 8 Image 61 (OCR) ===
—

=== Page 8 Image 62 (OCR) ===
oe

=== Page 8 Image 63 (OCR) ===
a

=== Page 8 Image 64 (OCR) ===
Qunoue).

=== Page 8 Image 66 (OCR) ===
guaoue)

=== Page 8 Image 67 (OCR) ===
a

=== Page 8 Image 68 (OCR) ===
uaoue).

=== Page 8 Image 69 (OCR) ===
euaoue).

=== Page 8 Image 70 (OCR) ===
a

=== Page 9 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Collegium would need to double current share of Xtampza in order to break even
9
Potential impact of doubling Xtampza share through exclusive contracts with additional payors
14
Current loss 
from 
operations
2020 
operating 
income
Loss due to 
market 
decline
Growth from 
existing 
account
Growth 
from new 
account
COGS increase
0
32
19
15
50
Key 
assumptions:
• ERO market 
continues to 
decline at -15% 
year on year 
until 2020
• GtN of sales with 
new account: 
60%
• Nucynta sales 
remains the 
same
• SG&A remains 
the same
Projected 2020 Xtampza  financial performance 
($ Millions)
DIRECTIONAL ESTIMATION
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 9 Image 1 (OCR) ===
—

=== Page 9 Image 2 (OCR) ===
oe

=== Page 9 Image 3 (OCR) ===
a

=== Page 9 Image 4 (OCR) ===
Qunoue).

=== Page 9 Image 6 (OCR) ===
guaoue)

=== Page 9 Image 7 (OCR) ===
a

=== Page 9 Image 8 (OCR) ===
uaoue).

=== Page 9 Image 9 (OCR) ===
euaoue).

=== Page 9 Image 10 (OCR) ===
a

=== Page 9 Image 11 (OCR) ===
—

=== Page 9 Image 12 (OCR) ===
oe

=== Page 9 Image 13 (OCR) ===
a

=== Page 9 Image 14 (OCR) ===
Qunoue).

=== Page 9 Image 16 (OCR) ===
guaoue)

=== Page 9 Image 17 (OCR) ===
a

=== Page 9 Image 18 (OCR) ===
uaoue).

=== Page 9 Image 19 (OCR) ===
euaoue).

=== Page 9 Image 20 (OCR) ===
a

=== Page 9 Image 21 (OCR) ===
—

=== Page 9 Image 22 (OCR) ===
oe

=== Page 9 Image 23 (OCR) ===
a

=== Page 9 Image 24 (OCR) ===
Qunoue).

=== Page 9 Image 26 (OCR) ===
guaoue)

=== Page 9 Image 27 (OCR) ===
a

=== Page 9 Image 28 (OCR) ===
uaoue).

=== Page 9 Image 29 (OCR) ===
euaoue).

=== Page 9 Image 30 (OCR) ===
a

=== Page 9 Image 31 (OCR) ===
—

=== Page 9 Image 32 (OCR) ===
oe

=== Page 9 Image 33 (OCR) ===
a

=== Page 9 Image 34 (OCR) ===
Qunoue).

=== Page 9 Image 36 (OCR) ===
guaoue)

=== Page 9 Image 37 (OCR) ===
a

=== Page 9 Image 38 (OCR) ===
uaoue).

=== Page 9 Image 39 (OCR) ===
euaoue).

=== Page 9 Image 40 (OCR) ===
a

=== Page 9 Image 41 (OCR) ===
—

=== Page 9 Image 42 (OCR) ===
oe

=== Page 9 Image 43 (OCR) ===
a

=== Page 9 Image 44 (OCR) ===
Qunoue).

=== Page 9 Image 46 (OCR) ===
guaoue)

=== Page 9 Image 47 (OCR) ===
a

=== Page 9 Image 48 (OCR) ===
uaoue).

=== Page 9 Image 49 (OCR) ===
euaoue).

=== Page 9 Image 50 (OCR) ===
a

=== Page 9 Image 51 (OCR) ===
—

=== Page 9 Image 52 (OCR) ===
oe

=== Page 9 Image 53 (OCR) ===
a

=== Page 9 Image 54 (OCR) ===
Qunoue).

=== Page 9 Image 56 (OCR) ===
guaoue)

=== Page 9 Image 57 (OCR) ===
a

=== Page 9 Image 58 (OCR) ===
uaoue).

=== Page 9 Image 59 (OCR) ===
euaoue).

=== Page 9 Image 60 (OCR) ===
a

=== Page 9 Image 61 (OCR) ===
—

=== Page 9 Image 62 (OCR) ===
oe

=== Page 9 Image 63 (OCR) ===
a

=== Page 9 Image 64 (OCR) ===
Qunoue).

=== Page 9 Image 66 (OCR) ===
guaoue)

=== Page 9 Image 67 (OCR) ===
a

=== Page 9 Image 68 (OCR) ===
uaoue).

=== Page 9 Image 69 (OCR) ===
euaoue).

=== Page 9 Image 70 (OCR) ===
a

=== Page 10 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Overview of top accounts across Commercial and Medicare: current view
10
Net sales1
$M
Market 
segment
Commer-
cial
11%
7%
6%
2%
2%
1%
1%
1%
1%
1%
11%
5%
2%
1%
1%
0%
54%
21%
17%
13%
21%
23%
20%
4%
9%
3%
5%
26%
14%
14%
15%
17%
14%
42%
35%
38%
21%
28%
29%
0%
20%
0%
0%
56%
66%
38%
40%
37%
28%
112
992
193
21
102
26
21
7
12
11
6
258
155
26
20
8
5
10
73
17
18
113
63
15
9
6
6
113
13
17
53
5
4
545
2019 contracting
Medicare 
Part D
Current status (FYE June 2018)
1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; 
3 Assuming status carries over from 201807 period for those accounts with OxyContin formulary access, status based on majority of lives; 4 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other 
prime accounts 
Account
Express Scripts
Caremark
OptumRx  - United Healthcare
Aetna Health Plans
Prime Therapeutics - excl HCSC4
Prime Therapeutics - HCSC
Cigna Healthcare
Procare
BCBS FL (Prime Therapeutics)
Independence BCBS (PA)
Caremark
OptumRx  - United Healthcare
Express Scripts
Prime Therapeutics
EnvisionRx Options
Total
Gross sales
$M 
Market 
Share
% 
Net sales 
OxyContin
2T Preferred
NOF
NOF
2T Preferred
NOF
3T Preferred
3T Pref PDP/MAPD NOF
Pref MAPD/PDP NOF
2T Preferred
2T Preferred
2T Preferred 
2T Preferred
2T Preferred
2T Preferred
NOF
MedImpact
2T Preferred
Rebate2
Xtampza ER3
Non-preferred
Preferred
Preferred
Non-preferred
Preferred
NOF
Preferred
NOF
NOF
NOF
Non-preferred
Non-preferred
Preferred
Non-preferred
Preferred
Preferred
2019 formulary status
Collegium is 
likely to 
double 
down on big 
national 
accounts in 
order to 
achieve 
break-even
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 10 Image 1 (OCR) ===
—

=== Page 10 Image 2 (OCR) ===
oe

=== Page 10 Image 3 (OCR) ===
a

=== Page 10 Image 4 (OCR) ===
Qunoue).

=== Page 10 Image 6 (OCR) ===
guaoue)

=== Page 10 Image 7 (OCR) ===
a

=== Page 10 Image 8 (OCR) ===
uaoue).

=== Page 10 Image 9 (OCR) ===
euaoue).

=== Page 10 Image 10 (OCR) ===
a

=== Page 10 Image 11 (OCR) ===
—

=== Page 10 Image 12 (OCR) ===
oe

=== Page 10 Image 13 (OCR) ===
a

=== Page 10 Image 14 (OCR) ===
Qunoue).

=== Page 10 Image 16 (OCR) ===
guaoue)

=== Page 10 Image 17 (OCR) ===
a

=== Page 10 Image 18 (OCR) ===
uaoue).

=== Page 10 Image 19 (OCR) ===
euaoue).

=== Page 10 Image 20 (OCR) ===
a

=== Page 10 Image 21 (OCR) ===
—

=== Page 10 Image 22 (OCR) ===
oe

=== Page 10 Image 23 (OCR) ===
a

=== Page 10 Image 24 (OCR) ===
Qunoue).

=== Page 10 Image 26 (OCR) ===
guaoue)

=== Page 10 Image 27 (OCR) ===
a

=== Page 10 Image 28 (OCR) ===
uaoue).

=== Page 10 Image 29 (OCR) ===
euaoue).

=== Page 10 Image 30 (OCR) ===
a

=== Page 10 Image 31 (OCR) ===
—

=== Page 10 Image 32 (OCR) ===
oe

=== Page 10 Image 33 (OCR) ===
a

=== Page 10 Image 34 (OCR) ===
Qunoue).

=== Page 10 Image 36 (OCR) ===
guaoue)

=== Page 10 Image 37 (OCR) ===
a

=== Page 10 Image 38 (OCR) ===
uaoue).

=== Page 10 Image 39 (OCR) ===
euaoue).

=== Page 10 Image 40 (OCR) ===
a

=== Page 10 Image 41 (OCR) ===
—

=== Page 10 Image 42 (OCR) ===
oe

=== Page 10 Image 43 (OCR) ===
a

=== Page 10 Image 44 (OCR) ===
Qunoue).

=== Page 10 Image 46 (OCR) ===
guaoue)

=== Page 10 Image 47 (OCR) ===
a

=== Page 10 Image 48 (OCR) ===
uaoue).

=== Page 10 Image 49 (OCR) ===
euaoue).

=== Page 10 Image 50 (OCR) ===
a

=== Page 10 Image 51 (OCR) ===
—

=== Page 10 Image 52 (OCR) ===
oe

=== Page 10 Image 53 (OCR) ===
a

=== Page 10 Image 54 (OCR) ===
Qunoue).

=== Page 10 Image 56 (OCR) ===
guaoue)

=== Page 10 Image 57 (OCR) ===
a

=== Page 10 Image 58 (OCR) ===
uaoue).

=== Page 10 Image 59 (OCR) ===
euaoue).

=== Page 10 Image 60 (OCR) ===
a

=== Page 10 Image 61 (OCR) ===
—

=== Page 10 Image 62 (OCR) ===
oe

=== Page 10 Image 63 (OCR) ===
a

=== Page 10 Image 64 (OCR) ===
Qunoue).

=== Page 10 Image 66 (OCR) ===
guaoue)

=== Page 10 Image 67 (OCR) ===
a

=== Page 10 Image 68 (OCR) ===
uaoue).

=== Page 10 Image 69 (OCR) ===
euaoue).

=== Page 10 Image 70 (OCR) ===
a

=== Page 11 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Current access status: OxyContin is preferred for 47% of lives on Prime’s Part D formularies
11
SOURCE: MMIT
• OxyContin is the preferred oxycodone with access to nearly half of Prime lives while Xtampza ER is excluded
• Zohydro ER is the preferred branded hydrocodone product (Hysingla ER is completely excluded), and Nucynta also maintains access 
to half of Prime lives
531
94
8
26
575
25552
Privileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal 
and regulatory review before they can be considered final. These materials are confidential and proprietary.
1 Includes ~10K lives where no PA/ST required for OxyContin and Nucynta
2 Defined as percentage of lives that are either preferred or covered (including PA/ST)
Lives, K
Overall formulary 
status
Lives, 
%
Hysingl
a ER
Xtampz
a ER
OxyCo
ntin
Nucynt
a ER
Zohydr
o ER
1,235
Overall covered 
lives %2
0%
0%
47%
47%
92%
Largest formulary
47
%
Collegium 
excluded1 
Not 
Covered
Not 
Covered
Preferre
d 
(PA/ST)
Preferred 
(PA/ST)
Covered 
(PA/ST)
BCBS FL BlueMedicare Classic 
and Choice 
43%
Only Zohydro - 
covered
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Covered 
(PA/ST) 
HISC Blue Medicare Rx (PDP) 
Plus and Value 
8%
No branded ERO 
coverage
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Regence BCBS of Oregon 
MedAdvantage + RxClassic PPO 
+ RxEnhanced PPO 
2%
Only Zohydro - 
preferred
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Preferred 
(PA/ST)
Blue Cross Community MMAI 
1
%
OxyContin and 
Zohydro 
preferred
Not 
Covered
Not 
Covered
Preferre
d 
(PA/ST)
Not 
Covered
Preferred 
(PA/ST)
Blue Cross Blue Shield of 
Minnesota SecureBlue 
Coverage status of leading ERO brands, 
Nov 2018
PRIME
Total
Oxycontin Covered
Not covered
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 11 Image 1 (OCR) ===
—

=== Page 11 Image 2 (OCR) ===
oe

=== Page 11 Image 3 (OCR) ===
a

=== Page 11 Image 4 (OCR) ===
Qunoue).

=== Page 11 Image 6 (OCR) ===
guaoue)

=== Page 11 Image 7 (OCR) ===
a

=== Page 11 Image 8 (OCR) ===
uaoue).

=== Page 11 Image 9 (OCR) ===
euaoue).

=== Page 11 Image 10 (OCR) ===
a

=== Page 11 Image 11 (OCR) ===
—

=== Page 11 Image 12 (OCR) ===
oe

=== Page 11 Image 13 (OCR) ===
a

=== Page 11 Image 14 (OCR) ===
Qunoue).

=== Page 11 Image 16 (OCR) ===
guaoue)

=== Page 11 Image 17 (OCR) ===
a

=== Page 11 Image 18 (OCR) ===
uaoue).

=== Page 11 Image 19 (OCR) ===
euaoue).

=== Page 11 Image 20 (OCR) ===
a

=== Page 11 Image 21 (OCR) ===
—

=== Page 11 Image 22 (OCR) ===
oe

=== Page 11 Image 23 (OCR) ===
a

=== Page 11 Image 24 (OCR) ===
Qunoue).

=== Page 11 Image 26 (OCR) ===
guaoue)

=== Page 11 Image 27 (OCR) ===
a

=== Page 11 Image 28 (OCR) ===
uaoue).

=== Page 11 Image 29 (OCR) ===
euaoue).

=== Page 11 Image 30 (OCR) ===
a

=== Page 11 Image 31 (OCR) ===
—

=== Page 11 Image 32 (OCR) ===
oe

=== Page 11 Image 33 (OCR) ===
a

=== Page 11 Image 34 (OCR) ===
Qunoue).

=== Page 11 Image 36 (OCR) ===
guaoue)

=== Page 11 Image 37 (OCR) ===
a

=== Page 11 Image 38 (OCR) ===
uaoue).

=== Page 11 Image 39 (OCR) ===
euaoue).

=== Page 11 Image 40 (OCR) ===
a

=== Page 11 Image 41 (OCR) ===
—

=== Page 11 Image 42 (OCR) ===
oe

=== Page 11 Image 43 (OCR) ===
a

=== Page 11 Image 44 (OCR) ===
Qunoue).

=== Page 11 Image 46 (OCR) ===
guaoue)

=== Page 11 Image 47 (OCR) ===
a

=== Page 11 Image 48 (OCR) ===
uaoue).

=== Page 11 Image 49 (OCR) ===
euaoue).

=== Page 11 Image 50 (OCR) ===
a

=== Page 11 Image 51 (OCR) ===
—

=== Page 11 Image 52 (OCR) ===
oe

=== Page 11 Image 53 (OCR) ===
a

=== Page 11 Image 54 (OCR) ===
Qunoue).

=== Page 11 Image 56 (OCR) ===
guaoue)

=== Page 11 Image 57 (OCR) ===
a

=== Page 11 Image 58 (OCR) ===
uaoue).

=== Page 11 Image 59 (OCR) ===
euaoue).

=== Page 11 Image 60 (OCR) ===
a

=== Page 11 Image 61 (OCR) ===
—

=== Page 11 Image 62 (OCR) ===
oe

=== Page 11 Image 63 (OCR) ===
a

=== Page 11 Image 64 (OCR) ===
Qunoue).

=== Page 11 Image 66 (OCR) ===
guaoue)

=== Page 11 Image 67 (OCR) ===
a

=== Page 11 Image 68 (OCR) ===
uaoue).

=== Page 11 Image 69 (OCR) ===
euaoue).

=== Page 11 Image 70 (OCR) ===
a

=== Page 12 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We defined potential 2020 access scenarios for Oxycontin vs. Xtampza
2020 Share shift assumptions under different scenarios, 2020 Q4 
2020 access 
scenarios
Continue current 
access status as 
exclusive preferred 
oxycodone ER
1
1
1
2
3
15
18
7
14
4
4
10
4
4
10
6
5
5
6
7
5
8
4
18
18
18
18
18
18
Oxycontin
Other brands
Xtampza
Share by products (exit share) 
Share shift vs. 
status quo 
Xtampza covered 
(non-preferred), 
while OxyContin 
stays preferred
2
Low
Hig
h
5%
35%
Xtampza replaces 
Oxycontin as 
exclusive preferred 
with 
grandfathering
3
Low
Hig
h
35%
55%
Oxycontin Excluded 
without 
grandfathering
4
Low
Hig
h
50%
70%
0%
ENVISION
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 12 Image 1 (OCR) ===
—

=== Page 12 Image 2 (OCR) ===
oe

=== Page 12 Image 3 (OCR) ===
a

=== Page 12 Image 4 (OCR) ===
Qunoue).

=== Page 12 Image 6 (OCR) ===
guaoue)

=== Page 12 Image 7 (OCR) ===
a

=== Page 12 Image 8 (OCR) ===
uaoue).

=== Page 12 Image 9 (OCR) ===
euaoue).

=== Page 12 Image 10 (OCR) ===
a

=== Page 12 Image 11 (OCR) ===
—

=== Page 12 Image 12 (OCR) ===
oe

=== Page 12 Image 13 (OCR) ===
a

=== Page 12 Image 14 (OCR) ===
Qunoue).

=== Page 12 Image 16 (OCR) ===
guaoue)

=== Page 12 Image 17 (OCR) ===
a

=== Page 12 Image 18 (OCR) ===
uaoue).

=== Page 12 Image 19 (OCR) ===
euaoue).

=== Page 12 Image 20 (OCR) ===
a

=== Page 12 Image 21 (OCR) ===
—

=== Page 12 Image 22 (OCR) ===
oe

=== Page 12 Image 23 (OCR) ===
a

=== Page 12 Image 24 (OCR) ===
Qunoue).

=== Page 12 Image 26 (OCR) ===
guaoue)

=== Page 12 Image 27 (OCR) ===
a

=== Page 12 Image 28 (OCR) ===
uaoue).

=== Page 12 Image 29 (OCR) ===
euaoue).

=== Page 12 Image 30 (OCR) ===
a

=== Page 12 Image 31 (OCR) ===
—

=== Page 12 Image 32 (OCR) ===
oe

=== Page 12 Image 33 (OCR) ===
a

=== Page 12 Image 34 (OCR) ===
Qunoue).

=== Page 12 Image 36 (OCR) ===
guaoue)

=== Page 12 Image 37 (OCR) ===
a

=== Page 12 Image 38 (OCR) ===
uaoue).

=== Page 12 Image 39 (OCR) ===
euaoue).

=== Page 12 Image 40 (OCR) ===
a

=== Page 12 Image 41 (OCR) ===
—

=== Page 12 Image 42 (OCR) ===
oe

=== Page 12 Image 43 (OCR) ===
a

=== Page 12 Image 44 (OCR) ===
Qunoue).

=== Page 12 Image 46 (OCR) ===
guaoue)

=== Page 12 Image 47 (OCR) ===
a

=== Page 12 Image 48 (OCR) ===
uaoue).

=== Page 12 Image 49 (OCR) ===
euaoue).

=== Page 12 Image 50 (OCR) ===
a

=== Page 12 Image 51 (OCR) ===
—

=== Page 12 Image 52 (OCR) ===
oe

=== Page 12 Image 53 (OCR) ===
a

=== Page 12 Image 54 (OCR) ===
Qunoue).

=== Page 12 Image 56 (OCR) ===
guaoue)

=== Page 12 Image 57 (OCR) ===
a

=== Page 12 Image 58 (OCR) ===
uaoue).

=== Page 12 Image 59 (OCR) ===
euaoue).

=== Page 12 Image 60 (OCR) ===
a

=== Page 12 Image 61 (OCR) ===
—

=== Page 12 Image 62 (OCR) ===
oe

=== Page 12 Image 63 (OCR) ===
a

=== Page 12 Image 64 (OCR) ===
Qunoue).

=== Page 12 Image 66 (OCR) ===
guaoue)

=== Page 12 Image 67 (OCR) ===
a

=== Page 12 Image 68 (OCR) ===
uaoue).

=== Page 12 Image 69 (OCR) ===
euaoue).

=== Page 12 Image 70 (OCR) ===
a

=== Page 13 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios
1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”
2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering 
5.9
6.8
6.8
6.2
4.9
5.8
4.8
4.4
Access 
scenarios tested
Xtampza 
covered (non-
preferred), 
while 
OxyContin 
stays 
preferred
Continue 
current 
access status 
as exclusive 
preferred 
oxycodone ER
Xtampza 
replaces 
Oxycontin as 
exclusive 
preferred with 
grandfatherin
gOxycontin 
Excluded 
without 
grandfatherin
g
Xtampza net 
sales ($M)
1
2
3
0%
50%
70%
70%
Assumed 
Xtampza 
rebate
Implication on Oxycontin bidding strategy
s to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. 
0.5
0.2
0.7
0.4
0.5
0.7
Share by 
product
Other brand 
net sales 
($M)
4
5
3
4
1
14
4
4
10
4
10
5
6
7
7
5
6
8
4
18
18
18
18
18
17
2.1
1.4
1.9
1.9
2.2
2.4
Oxycontin
Xtampza
Other brands
Sha
re 
shif
t
Low
Hig
h
Low
Hig
h
Low
Hig
h
Low
Hig
h
ENVISION
15
2
1 18
0.7
0.8
46%
Break-
even 
rebate2 
31%
35%
N/A
13%
33%
Net sales at min 
rebate ($M)
Rebate rate to keep 
Envision whole1 
32%
22%
29%
N/A
8%
10%
24%
Theoretic
al – 
unlikely 
able to 
lower 
current 
rate 
(40%)
16%
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 13 Image 1 (OCR) ===
—

=== Page 13 Image 2 (OCR) ===
oe

=== Page 13 Image 3 (OCR) ===
a

=== Page 13 Image 4 (OCR) ===
Qunoue).

=== Page 13 Image 6 (OCR) ===
guaoue)

=== Page 13 Image 7 (OCR) ===
a

=== Page 13 Image 8 (OCR) ===
uaoue).

=== Page 13 Image 9 (OCR) ===
euaoue).

=== Page 13 Image 10 (OCR) ===
a

=== Page 13 Image 11 (OCR) ===
—

=== Page 13 Image 12 (OCR) ===
oe

=== Page 13 Image 13 (OCR) ===
a

=== Page 13 Image 14 (OCR) ===
Qunoue).

=== Page 13 Image 16 (OCR) ===
guaoue)

=== Page 13 Image 17 (OCR) ===
a

=== Page 13 Image 18 (OCR) ===
uaoue).

=== Page 13 Image 19 (OCR) ===
euaoue).

=== Page 13 Image 20 (OCR) ===
a

=== Page 13 Image 21 (OCR) ===
—

=== Page 13 Image 22 (OCR) ===
oe

=== Page 13 Image 23 (OCR) ===
a

=== Page 13 Image 24 (OCR) ===
Qunoue).

=== Page 13 Image 26 (OCR) ===
guaoue)

=== Page 13 Image 27 (OCR) ===
a

=== Page 13 Image 28 (OCR) ===
uaoue).

=== Page 13 Image 29 (OCR) ===
euaoue).

=== Page 13 Image 30 (OCR) ===
a

=== Page 13 Image 31 (OCR) ===
—

=== Page 13 Image 32 (OCR) ===
oe

=== Page 13 Image 33 (OCR) ===
a

=== Page 13 Image 34 (OCR) ===
Qunoue).

=== Page 13 Image 36 (OCR) ===
guaoue)

=== Page 13 Image 37 (OCR) ===
a

=== Page 13 Image 38 (OCR) ===
uaoue).

=== Page 13 Image 39 (OCR) ===
euaoue).

=== Page 13 Image 40 (OCR) ===
a

=== Page 13 Image 41 (OCR) ===
—

=== Page 13 Image 42 (OCR) ===
oe

=== Page 13 Image 43 (OCR) ===
a

=== Page 13 Image 44 (OCR) ===
Qunoue).

=== Page 13 Image 46 (OCR) ===
guaoue)

=== Page 13 Image 47 (OCR) ===
a

=== Page 13 Image 48 (OCR) ===
uaoue).

=== Page 13 Image 49 (OCR) ===
euaoue).

=== Page 13 Image 50 (OCR) ===
a

=== Page 13 Image 51 (OCR) ===
—

=== Page 13 Image 52 (OCR) ===
oe

=== Page 13 Image 53 (OCR) ===
a

=== Page 13 Image 54 (OCR) ===
Qunoue).

=== Page 13 Image 56 (OCR) ===
guaoue)

=== Page 13 Image 57 (OCR) ===
a

=== Page 13 Image 58 (OCR) ===
uaoue).

=== Page 13 Image 59 (OCR) ===
euaoue).

=== Page 13 Image 60 (OCR) ===
a

=== Page 13 Image 61 (OCR) ===
—

=== Page 13 Image 62 (OCR) ===
oe

=== Page 13 Image 63 (OCR) ===
a

=== Page 13 Image 64 (OCR) ===
Qunoue).

=== Page 13 Image 66 (OCR) ===
guaoue)

=== Page 13 Image 67 (OCR) ===
a

=== Page 13 Image 68 (OCR) ===
uaoue).

=== Page 13 Image 69 (OCR) ===
euaoue).

=== Page 13 Image 70 (OCR) ===
a

=== Page 14 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
High level assessment of potential strategic options for Oxycontin
1 Only include Commercial and Part D accounts
2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza losing 60-70%% of the market share due to exclusion
2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza share grow by 10-40% YoY
3 Assuming  Oxycontin share drops by 65%  in 2020  and by 30% YoY in 2021 and 2022 due to exclusion, and Xtampza captures 75% of the share drop from Oxycontin
Key assumptions, 2022
3 year financial projection of net sales1 (after rebates and other GtN 
reductions)
Maintaining current access status could offer highest cumulative net 
sales in the longer term 
13
%2 
2%4
10
%3
Oxycontin 
Share
Oxycontin 
rebate
Commercial: 
50%
Medicare: 
70%
0%
Commercial: 
45%
Medicare: 
69%
(assuming 
2% increase 
YoY)
Oxycontin net sales1 ($M) 
Xtampza net sales1 ($M)
273
227
202
702
Secure 
exclusive 
position 
across all 
contracted 
accounts 
Maintain 
current 
access 
status with 
increasing 
rebates
Pull away 
rebates 
from all 
accounts
xx
3 year 
total
297
240
206
270
179
128
2020
21
2022
743
577
14
19
34
44
55
47
66
65
69
120
115
113
21
2020
2022
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 14 Image 1 (OCR) ===
—

=== Page 14 Image 2 (OCR) ===
oe

=== Page 14 Image 3 (OCR) ===
a

=== Page 14 Image 4 (OCR) ===
Qunoue).

=== Page 14 Image 6 (OCR) ===
guaoue)

=== Page 14 Image 7 (OCR) ===
a

=== Page 14 Image 8 (OCR) ===
uaoue).

=== Page 14 Image 9 (OCR) ===
euaoue).

=== Page 14 Image 10 (OCR) ===
a

=== Page 14 Image 11 (OCR) ===
—

=== Page 14 Image 12 (OCR) ===
oe

=== Page 14 Image 13 (OCR) ===
a

=== Page 14 Image 14 (OCR) ===
Qunoue).

=== Page 14 Image 16 (OCR) ===
guaoue)

=== Page 14 Image 17 (OCR) ===
a

=== Page 14 Image 18 (OCR) ===
uaoue).

=== Page 14 Image 19 (OCR) ===
euaoue).

=== Page 14 Image 20 (OCR) ===
a

=== Page 14 Image 21 (OCR) ===
—

=== Page 14 Image 22 (OCR) ===
oe

=== Page 14 Image 23 (OCR) ===
a

=== Page 14 Image 24 (OCR) ===
Qunoue).

=== Page 14 Image 26 (OCR) ===
guaoue)

=== Page 14 Image 27 (OCR) ===
a

=== Page 14 Image 28 (OCR) ===
uaoue).

=== Page 14 Image 29 (OCR) ===
euaoue).

=== Page 14 Image 30 (OCR) ===
a

=== Page 14 Image 31 (OCR) ===
—

=== Page 14 Image 32 (OCR) ===
oe

=== Page 14 Image 33 (OCR) ===
a

=== Page 14 Image 34 (OCR) ===
Qunoue).

=== Page 14 Image 36 (OCR) ===
guaoue)

=== Page 14 Image 37 (OCR) ===
a

=== Page 14 Image 38 (OCR) ===
uaoue).

=== Page 14 Image 39 (OCR) ===
euaoue).

=== Page 14 Image 40 (OCR) ===
a

=== Page 14 Image 41 (OCR) ===
—

=== Page 14 Image 42 (OCR) ===
oe

=== Page 14 Image 43 (OCR) ===
a

=== Page 14 Image 44 (OCR) ===
Qunoue).

=== Page 14 Image 46 (OCR) ===
guaoue)

=== Page 14 Image 47 (OCR) ===
a

=== Page 14 Image 48 (OCR) ===
uaoue).

=== Page 14 Image 49 (OCR) ===
euaoue).

=== Page 14 Image 50 (OCR) ===
a

=== Page 14 Image 51 (OCR) ===
—

=== Page 14 Image 52 (OCR) ===
oe

=== Page 14 Image 53 (OCR) ===
a

=== Page 14 Image 54 (OCR) ===
Qunoue).

=== Page 14 Image 56 (OCR) ===
guaoue)

=== Page 14 Image 57 (OCR) ===
a

=== Page 14 Image 58 (OCR) ===
uaoue).

=== Page 14 Image 59 (OCR) ===
euaoue).

=== Page 14 Image 60 (OCR) ===
a

=== Page 14 Image 61 (OCR) ===
—

=== Page 14 Image 62 (OCR) ===
oe

=== Page 14 Image 63 (OCR) ===
a

=== Page 14 Image 64 (OCR) ===
Qunoue).

=== Page 14 Image 66 (OCR) ===
guaoue)

=== Page 14 Image 67 (OCR) ===
a

=== Page 14 Image 68 (OCR) ===
uaoue).

=== Page 14 Image 69 (OCR) ===
euaoue).

=== Page 14 Image 70 (OCR) ===
a

=== Page 15 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
• OxyContin and Hysingla ER maintain strong access on Envision’s formularies, with OxyContin maintaining preferred status on 66% o
lives 
• Collegium’s products are nearly completely excluded on all Envision formularies
1 Defined as percentage of lives that are either preferred or covered (including PA/ST)
Current access status: OxyContin is preferred for 66% of lives on Envision Part D formularies
SOURCE: MMIT
25
466
203
27
51
Not 
Covered
Preferre
d
Covered 
(PA/ST)
Not 
Covered
Not 
Covered
Not 
Covered
Covered 
(PA/ST)
Preferre
d
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Privileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal 
and regulatory review before they can be considered final. These materials are confidential and proprietary.
MCS Classicare II
HealthSun MediMax 
Preferre
d
Not 
Covered
Preferre
d
Not 
Covered
EnvisionRxPlus PDP
Covered
Not 
Covered
Not 
Covered
Covered 
(PA/ST)
74%
1%
92%
0%
65%
EnvisionRxPlus Hybrid PDP
HealthTeam Advantage Plan
Covered 
(PA/ST)
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Lives, K
Overall formulary 
status
Lives, 
%
Hysingl
a ER
Xtampz
a ER
OxyCo
ntin
Nucynt
a ER
Zohydr
o ER
Largest formulary
Purdue 
preferred, 
Zohydro covered
Only Oxycontin 
covered
Purdue portfolio 
exclusive 
coverage 
Only branded 
hydrocodone 
coverage
Only Hysingla ER 
covered
Overall covered 
lives %1
59
%
26
%
7%
3%
3%
Oxycontin Covered
Not cov
Coverage status of leading ERO brands, 
Nov 2018
ENVISION
789
Total
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 15 Image 1 (OCR) ===
—

=== Page 15 Image 2 (OCR) ===
oe

=== Page 15 Image 3 (OCR) ===
a

=== Page 15 Image 4 (OCR) ===
Qunoue).

=== Page 15 Image 6 (OCR) ===
guaoue)

=== Page 15 Image 7 (OCR) ===
a

=== Page 15 Image 8 (OCR) ===
uaoue).

=== Page 15 Image 9 (OCR) ===
euaoue).

=== Page 15 Image 10 (OCR) ===
a

=== Page 15 Image 11 (OCR) ===
—

=== Page 15 Image 12 (OCR) ===
oe

=== Page 15 Image 13 (OCR) ===
a

=== Page 15 Image 14 (OCR) ===
Qunoue).

=== Page 15 Image 16 (OCR) ===
guaoue)

=== Page 15 Image 17 (OCR) ===
a

=== Page 15 Image 18 (OCR) ===
uaoue).

=== Page 15 Image 19 (OCR) ===
euaoue).

=== Page 15 Image 20 (OCR) ===
a

=== Page 15 Image 21 (OCR) ===
—

=== Page 15 Image 22 (OCR) ===
oe

=== Page 15 Image 23 (OCR) ===
a

=== Page 15 Image 24 (OCR) ===
Qunoue).

=== Page 15 Image 26 (OCR) ===
guaoue)

=== Page 15 Image 27 (OCR) ===
a

=== Page 15 Image 28 (OCR) ===
uaoue).

=== Page 15 Image 29 (OCR) ===
euaoue).

=== Page 15 Image 30 (OCR) ===
a

=== Page 15 Image 31 (OCR) ===
—

=== Page 15 Image 32 (OCR) ===
oe

=== Page 15 Image 33 (OCR) ===
a

=== Page 15 Image 34 (OCR) ===
Qunoue).

=== Page 15 Image 36 (OCR) ===
guaoue)

=== Page 15 Image 37 (OCR) ===
a

=== Page 15 Image 38 (OCR) ===
uaoue).

=== Page 15 Image 39 (OCR) ===
euaoue).

=== Page 15 Image 40 (OCR) ===
a

=== Page 15 Image 41 (OCR) ===
—

=== Page 15 Image 42 (OCR) ===
oe

=== Page 15 Image 43 (OCR) ===
a

=== Page 15 Image 44 (OCR) ===
Qunoue).

=== Page 15 Image 46 (OCR) ===
guaoue)

=== Page 15 Image 47 (OCR) ===
a

=== Page 15 Image 48 (OCR) ===
uaoue).

=== Page 15 Image 49 (OCR) ===
euaoue).

=== Page 15 Image 50 (OCR) ===
a

=== Page 15 Image 51 (OCR) ===
—

=== Page 15 Image 52 (OCR) ===
oe

=== Page 15 Image 53 (OCR) ===
a

=== Page 15 Image 54 (OCR) ===
Qunoue).

=== Page 15 Image 56 (OCR) ===
guaoue)

=== Page 15 Image 57 (OCR) ===
a

=== Page 15 Image 58 (OCR) ===
uaoue).

=== Page 15 Image 59 (OCR) ===
euaoue).

=== Page 15 Image 60 (OCR) ===
a

=== Page 15 Image 61 (OCR) ===
—

=== Page 15 Image 62 (OCR) ===
oe

=== Page 15 Image 63 (OCR) ===
a

=== Page 15 Image 64 (OCR) ===
Qunoue).

=== Page 15 Image 66 (OCR) ===
guaoue)

=== Page 15 Image 67 (OCR) ===
a

=== Page 15 Image 68 (OCR) ===
uaoue).

=== Page 15 Image 69 (OCR) ===
euaoue).

=== Page 15 Image 70 (OCR) ===
a

=== Page 16 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We defined potential 2020 access scenarios for Oxycontin vs. Xtampza
2020 Share shift assumptions under different scenarios, 2020 Q4 
2020 access 
scenarios
Continue current 
access status as  
exclusive preferred 
oxycodone ER
1
Both Oxycontin and 
Xtampza preferred 
2
Xtampza preferred, 
Oxycontin non-
preferred
3
Xtampza replaces 
Oxycontin as 
exclusive preferred 
with 
grandfathering
4
Oxycontin Excluded 
without 
grandfathering
5
5
1
6
15
8
7
8
3
12
9
5
4
11
8
9
6
8
6
9
8
9
7
6
9
3
10
7
Oxycontin
Xtampza
Other 
Share by products (exit share) 
Share shift vs. 
status quo 
Low
Hig
h
Low
Hig
h
Low
Hig
h
Low
Hig
h
20%
40%
30%
68%
50%
70%
60%
80%
0%
PRIME
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 16 Image 1 (OCR) ===
—

=== Page 16 Image 2 (OCR) ===
oe

=== Page 16 Image 3 (OCR) ===
a

=== Page 16 Image 4 (OCR) ===
Qunoue).

=== Page 16 Image 6 (OCR) ===
guaoue)

=== Page 16 Image 7 (OCR) ===
a

=== Page 16 Image 8 (OCR) ===
uaoue).

=== Page 16 Image 9 (OCR) ===
euaoue).

=== Page 16 Image 10 (OCR) ===
a

=== Page 16 Image 11 (OCR) ===
—

=== Page 16 Image 12 (OCR) ===
oe

=== Page 16 Image 13 (OCR) ===
a

=== Page 16 Image 14 (OCR) ===
Qunoue).

=== Page 16 Image 16 (OCR) ===
guaoue)

=== Page 16 Image 17 (OCR) ===
a

=== Page 16 Image 18 (OCR) ===
uaoue).

=== Page 16 Image 19 (OCR) ===
euaoue).

=== Page 16 Image 20 (OCR) ===
a

=== Page 16 Image 21 (OCR) ===
—

=== Page 16 Image 22 (OCR) ===
oe

=== Page 16 Image 23 (OCR) ===
a

=== Page 16 Image 24 (OCR) ===
Qunoue).

=== Page 16 Image 26 (OCR) ===
guaoue)

=== Page 16 Image 27 (OCR) ===
a

=== Page 16 Image 28 (OCR) ===
uaoue).

=== Page 16 Image 29 (OCR) ===
euaoue).

=== Page 16 Image 30 (OCR) ===
a

=== Page 16 Image 31 (OCR) ===
—

=== Page 16 Image 32 (OCR) ===
oe

=== Page 16 Image 33 (OCR) ===
a

=== Page 16 Image 34 (OCR) ===
Qunoue).

=== Page 16 Image 36 (OCR) ===
guaoue)

=== Page 16 Image 37 (OCR) ===
a

=== Page 16 Image 38 (OCR) ===
uaoue).

=== Page 16 Image 39 (OCR) ===
euaoue).

=== Page 16 Image 40 (OCR) ===
a

=== Page 16 Image 41 (OCR) ===
—

=== Page 16 Image 42 (OCR) ===
oe

=== Page 16 Image 43 (OCR) ===
a

=== Page 16 Image 44 (OCR) ===
Qunoue).

=== Page 16 Image 46 (OCR) ===
guaoue)

=== Page 16 Image 47 (OCR) ===
a

=== Page 16 Image 48 (OCR) ===
uaoue).

=== Page 16 Image 49 (OCR) ===
euaoue).

=== Page 16 Image 50 (OCR) ===
a

=== Page 16 Image 51 (OCR) ===
—

=== Page 16 Image 52 (OCR) ===
oe

=== Page 16 Image 53 (OCR) ===
a

=== Page 16 Image 54 (OCR) ===
Qunoue).

=== Page 16 Image 56 (OCR) ===
guaoue)

=== Page 16 Image 57 (OCR) ===
a

=== Page 16 Image 58 (OCR) ===
uaoue).

=== Page 16 Image 59 (OCR) ===
euaoue).

=== Page 16 Image 60 (OCR) ===
a

=== Page 16 Image 61 (OCR) ===
—

=== Page 16 Image 62 (OCR) ===
oe

=== Page 16 Image 63 (OCR) ===
a

=== Page 16 Image 64 (OCR) ===
Qunoue).

=== Page 16 Image 66 (OCR) ===
guaoue)

=== Page 16 Image 67 (OCR) ===
a

=== Page 16 Image 68 (OCR) ===
uaoue).

=== Page 16 Image 69 (OCR) ===
euaoue).

=== Page 16 Image 70 (OCR) ===
a

=== Page 17 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios
1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”
2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  
10.8
11.0
11.5
13.2
7.2
6.2
11.2
7.9
10.2
6.6
2020 access 
scenarios
Both 
Oxycontin and 
Xtampza 
preferred 
Xtampza 
preferred, 
Oxycontin 
non-preferred
Continue 
current access 
status as  
exclusive 
preferred
oxycodone ER
Xtampza 
replacing 
Oxycontin as 
exclusive 
preferred with 
grandfathering
Oxycontin 
Excluded 
without 
grandfatherin
g
Xtampza net 
sales ($M)
1
2
3
4
0%
40%
50%
70%
70%
Assumed 
Xtampza 
rebate
Implication on Oxycontin bidding strategy
 to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. 
2.1
3.2
0.8
2.9
1.6
1.1
1.8
1.6
Share by 
product, 2020 
Q4
Other brand 
net sales ($M)
5
3
22
9
8
7
12
22
6
4
5
9
6
8
11
9
7
6
8
22
8
5
9
8
9
7
10
3
22
22
22
22
22
8.0
7.3
7.7
8.8
8.4
8.8
9.2
9.6
Oxycontin
Other brands
Xtampza
PRIME
0.7
22
6
1
15
6.5
Low
High
Low
High
Low
High
Low
High
Low
High
Shar
e 
shift
Break-
even 
rebate2 
37%
48%
32%
37%
N/A
30%
44%
60%
45%
Net sales at min 
rebate ($M)
42%
Rebate rate to keep 
Prime whole1 
30%
44%
27%
40%
N/A
24%
36%
32%
Theoretic
al – 
unlikely 
able to 
lower 
current 
rate 
(40%)
4
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 17 Image 1 (OCR) ===
—

=== Page 17 Image 2 (OCR) ===
oe

=== Page 17 Image 3 (OCR) ===
a

=== Page 17 Image 4 (OCR) ===
Qunoue).

=== Page 17 Image 6 (OCR) ===
guaoue)

=== Page 17 Image 7 (OCR) ===
a

=== Page 17 Image 8 (OCR) ===
uaoue).

=== Page 17 Image 9 (OCR) ===
euaoue).

=== Page 17 Image 10 (OCR) ===
a

=== Page 17 Image 11 (OCR) ===
—

=== Page 17 Image 12 (OCR) ===
oe

=== Page 17 Image 13 (OCR) ===
a

=== Page 17 Image 14 (OCR) ===
Qunoue).

=== Page 17 Image 16 (OCR) ===
guaoue)

=== Page 17 Image 17 (OCR) ===
a

=== Page 17 Image 18 (OCR) ===
uaoue).

=== Page 17 Image 19 (OCR) ===
euaoue).

=== Page 17 Image 20 (OCR) ===
a

=== Page 17 Image 21 (OCR) ===
—

=== Page 17 Image 22 (OCR) ===
oe

=== Page 17 Image 23 (OCR) ===
a

=== Page 17 Image 24 (OCR) ===
Qunoue).

=== Page 17 Image 26 (OCR) ===
guaoue)

=== Page 17 Image 27 (OCR) ===
a

=== Page 17 Image 28 (OCR) ===
uaoue).

=== Page 17 Image 29 (OCR) ===
euaoue).

=== Page 17 Image 30 (OCR) ===
a

=== Page 17 Image 31 (OCR) ===
—

=== Page 17 Image 32 (OCR) ===
oe

=== Page 17 Image 33 (OCR) ===
a

=== Page 17 Image 34 (OCR) ===
Qunoue).

=== Page 17 Image 36 (OCR) ===
guaoue)

=== Page 17 Image 37 (OCR) ===
a

=== Page 17 Image 38 (OCR) ===
uaoue).

=== Page 17 Image 39 (OCR) ===
euaoue).

=== Page 17 Image 40 (OCR) ===
a

=== Page 17 Image 41 (OCR) ===
—

=== Page 17 Image 42 (OCR) ===
oe

=== Page 17 Image 43 (OCR) ===
a

=== Page 17 Image 44 (OCR) ===
Qunoue).

=== Page 17 Image 46 (OCR) ===
guaoue)

=== Page 17 Image 47 (OCR) ===
a

=== Page 17 Image 48 (OCR) ===
uaoue).

=== Page 17 Image 49 (OCR) ===
euaoue).

=== Page 17 Image 50 (OCR) ===
a

=== Page 17 Image 51 (OCR) ===
—

=== Page 17 Image 52 (OCR) ===
oe

=== Page 17 Image 53 (OCR) ===
a

=== Page 17 Image 54 (OCR) ===
Qunoue).

=== Page 17 Image 56 (OCR) ===
guaoue)

=== Page 17 Image 57 (OCR) ===
a

=== Page 17 Image 58 (OCR) ===
uaoue).

=== Page 17 Image 59 (OCR) ===
euaoue).

=== Page 17 Image 60 (OCR) ===
a

=== Page 17 Image 61 (OCR) ===
—

=== Page 17 Image 62 (OCR) ===
oe

=== Page 17 Image 63 (OCR) ===
a

=== Page 17 Image 64 (OCR) ===
Qunoue).

=== Page 17 Image 66 (OCR) ===
guaoue)

=== Page 17 Image 67 (OCR) ===
a

=== Page 17 Image 68 (OCR) ===
uaoue).

=== Page 17 Image 69 (OCR) ===
euaoue).

=== Page 17 Image 70 (OCR) ===
a

=== Page 18 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Long term view: 2020-2022 financial impact under different access scenarios
1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”
2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  
20.3
17.3
10.2
14.5
16.0
19.4
12.5
19.2
Access scenarios
Both Oxycontin 
and Xtampza 
preferred 
Xtampza 
preferred, 
Oxycontin non-
preferred
Continue current 
access status as  
exclusive preferred
oxycodone ER
Xtampza replacing 
Oxycontin as 
exclusive preferred 
with grandfathering
60%
50%
43%
5%
0%
Oxycontin 
Excluded without 
grandfathering
2020
1
2
3
4
Assumed 
Oxycontin 
rebate, 2022
3 year total ($M)
Share 
shift
Maintaining  current access status could maximize net sales in the longer term as well, assuming reasonable increase in rebate rate
6.6
10.6
9.6
8.7
10.2
7.5
10.6
11.1
Share by 
product, 2022 
Q4
2021
5
20
3
5
20
4
8
20
9
7
10
7
8
8
5
9
7
9
9
9
2
9
20
10
20
1
20
9
1
9
1
20
20
3.4
6.0
2.6
5.6
6.4
4.8
3.4
5.1
Oxycontin
Other brands
Xtampza
PRIME
10.8
0 6
13
20
7.3
Low
High
Low
High
Low
High
Low
High
Low
High
Oxycontin net sales ($M)
2022
4.3
2.8
3.3
1.5
2.5
1.6
2.4
1.0
2.0
22.4
5
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 18 Image 1 (OCR) ===
—

=== Page 18 Image 2 (OCR) ===
oe

=== Page 18 Image 3 (OCR) ===
a

=== Page 18 Image 4 (OCR) ===
Qunoue).

=== Page 18 Image 6 (OCR) ===
guaoue)

=== Page 18 Image 7 (OCR) ===
a

=== Page 18 Image 8 (OCR) ===
uaoue).

=== Page 18 Image 9 (OCR) ===
euaoue).

=== Page 18 Image 10 (OCR) ===
a

=== Page 18 Image 11 (OCR) ===
—

=== Page 18 Image 12 (OCR) ===
oe

=== Page 18 Image 13 (OCR) ===
a

=== Page 18 Image 14 (OCR) ===
Qunoue).

=== Page 18 Image 16 (OCR) ===
guaoue)

=== Page 18 Image 17 (OCR) ===
a

=== Page 18 Image 18 (OCR) ===
uaoue).

=== Page 18 Image 19 (OCR) ===
euaoue).

=== Page 18 Image 20 (OCR) ===
a

=== Page 18 Image 21 (OCR) ===
—

=== Page 18 Image 22 (OCR) ===
oe

=== Page 18 Image 23 (OCR) ===
a

=== Page 18 Image 24 (OCR) ===
Qunoue).

=== Page 18 Image 26 (OCR) ===
guaoue)

=== Page 18 Image 27 (OCR) ===
a

=== Page 18 Image 28 (OCR) ===
uaoue).

=== Page 18 Image 29 (OCR) ===
euaoue).

=== Page 18 Image 30 (OCR) ===
a

=== Page 18 Image 31 (OCR) ===
—

=== Page 18 Image 32 (OCR) ===
oe

=== Page 18 Image 33 (OCR) ===
a

=== Page 18 Image 34 (OCR) ===
Qunoue).

=== Page 18 Image 36 (OCR) ===
guaoue)

=== Page 18 Image 37 (OCR) ===
a

=== Page 18 Image 38 (OCR) ===
uaoue).

=== Page 18 Image 39 (OCR) ===
euaoue).

=== Page 18 Image 40 (OCR) ===
a

=== Page 18 Image 41 (OCR) ===
—

=== Page 18 Image 42 (OCR) ===
oe

=== Page 18 Image 43 (OCR) ===
a

=== Page 18 Image 44 (OCR) ===
Qunoue).

=== Page 18 Image 46 (OCR) ===
guaoue)

=== Page 18 Image 47 (OCR) ===
a

=== Page 18 Image 48 (OCR) ===
uaoue).

=== Page 18 Image 49 (OCR) ===
euaoue).

=== Page 18 Image 50 (OCR) ===
a

=== Page 18 Image 51 (OCR) ===
—

=== Page 18 Image 52 (OCR) ===
oe

=== Page 18 Image 53 (OCR) ===
a

=== Page 18 Image 54 (OCR) ===
Qunoue).

=== Page 18 Image 56 (OCR) ===
guaoue)

=== Page 18 Image 57 (OCR) ===
a

=== Page 18 Image 58 (OCR) ===
uaoue).

=== Page 18 Image 59 (OCR) ===
euaoue).

=== Page 18 Image 60 (OCR) ===
a

=== Page 18 Image 61 (OCR) ===
—

=== Page 18 Image 62 (OCR) ===
oe

=== Page 18 Image 63 (OCR) ===
a

=== Page 18 Image 64 (OCR) ===
Qunoue).

=== Page 18 Image 66 (OCR) ===
guaoue)

=== Page 18 Image 67 (OCR) ===
a

=== Page 18 Image 68 (OCR) ===
uaoue).

=== Page 18 Image 69 (OCR) ===
euaoue).

=== Page 18 Image 70 (OCR) ===
a

=== Page 19 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
BACKUP
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 19 Image 1 (OCR) ===
—

=== Page 19 Image 2 (OCR) ===
oe

=== Page 19 Image 3 (OCR) ===
a

=== Page 19 Image 4 (OCR) ===
Qunoue).

=== Page 19 Image 6 (OCR) ===
guaoue)

=== Page 19 Image 7 (OCR) ===
a

=== Page 19 Image 8 (OCR) ===
uaoue).

=== Page 19 Image 9 (OCR) ===
euaoue).

=== Page 19 Image 10 (OCR) ===
a

=== Page 19 Image 11 (OCR) ===
—

=== Page 19 Image 12 (OCR) ===
oe

=== Page 19 Image 13 (OCR) ===
a

=== Page 19 Image 14 (OCR) ===
Qunoue).

=== Page 19 Image 16 (OCR) ===
guaoue)

=== Page 19 Image 17 (OCR) ===
a

=== Page 19 Image 18 (OCR) ===
uaoue).

=== Page 19 Image 19 (OCR) ===
euaoue).

=== Page 19 Image 20 (OCR) ===
a

=== Page 19 Image 21 (OCR) ===
—

=== Page 19 Image 22 (OCR) ===
oe

=== Page 19 Image 23 (OCR) ===
a

=== Page 19 Image 24 (OCR) ===
Qunoue).

=== Page 19 Image 26 (OCR) ===
guaoue)

=== Page 19 Image 27 (OCR) ===
a

=== Page 19 Image 28 (OCR) ===
uaoue).

=== Page 19 Image 29 (OCR) ===
euaoue).

=== Page 19 Image 30 (OCR) ===
a

=== Page 19 Image 31 (OCR) ===
—

=== Page 19 Image 32 (OCR) ===
oe

=== Page 19 Image 33 (OCR) ===
a

=== Page 19 Image 34 (OCR) ===
Qunoue).

=== Page 19 Image 36 (OCR) ===
guaoue)

=== Page 19 Image 37 (OCR) ===
a

=== Page 19 Image 38 (OCR) ===
uaoue).

=== Page 19 Image 39 (OCR) ===
euaoue).

=== Page 19 Image 40 (OCR) ===
a

=== Page 19 Image 41 (OCR) ===
—

=== Page 19 Image 42 (OCR) ===
oe

=== Page 19 Image 43 (OCR) ===
a

=== Page 19 Image 44 (OCR) ===
Qunoue).

=== Page 19 Image 46 (OCR) ===
guaoue)

=== Page 19 Image 47 (OCR) ===
a

=== Page 19 Image 48 (OCR) ===
uaoue).

=== Page 19 Image 49 (OCR) ===
euaoue).

=== Page 19 Image 50 (OCR) ===
a

=== Page 19 Image 51 (OCR) ===
—

=== Page 19 Image 52 (OCR) ===
oe

=== Page 19 Image 53 (OCR) ===
a

=== Page 19 Image 54 (OCR) ===
Qunoue).

=== Page 19 Image 56 (OCR) ===
guaoue)

=== Page 19 Image 57 (OCR) ===
a

=== Page 19 Image 58 (OCR) ===
uaoue).

=== Page 19 Image 59 (OCR) ===
euaoue).

=== Page 19 Image 60 (OCR) ===
a

=== Page 19 Image 61 (OCR) ===
—

=== Page 19 Image 62 (OCR) ===
oe

=== Page 19 Image 63 (OCR) ===
a

=== Page 19 Image 64 (OCR) ===
Qunoue).

=== Page 19 Image 66 (OCR) ===
guaoue)

=== Page 19 Image 67 (OCR) ===
a

=== Page 19 Image 68 (OCR) ===
uaoue).

=== Page 19 Image 69 (OCR) ===
euaoue).

=== Page 19 Image 70 (OCR) ===
a

=== Page 20 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Assessment of current performance of Collegium
Collegium strategy going forward: key ingoing assumptions
• 2 product portfolio exclusively in pain management therapeutic area, with 
R&D pipeline all early life (Ph II or earlier) and concentrated in pain 
management1
• Facing “finite” market for its current portfolio, driven by:
– Overall U.S. ERO market continuing to decline (-15% YoY decline2 until 
2020)
– Likely genericization of extended-release oxycodone with abuse-deterrent 
formulations, leading to a market shift away from branded opioids
• Product portfolio is facing challenges
– Xtampza ER (oxycodone): $50.9M sales in Q1-Q3 20182
• Competing with an established market leader in a highly genericized class
– Nucynta (tapentadol): $156M sales in Q1-Q3 20182
• Slow launch since acquisition and experiencing share loss (-4% TRx from 
Q2-Q3 ’18)
• Collegium responsible for minimum $135M/yr royalty payment for first 4 
years of licensing regardless of product performance
• Collegium continues to invest in salesforce reps (~150) calling on specialists 
(~10,700) for both products
• Overall, Collegium is unprofitable ($31M loss from operations Q1-Q3 2018)
– ($0.50) EPS for Q3 ’18, missing Thomson Reuters’ consensus estimate of 
($0 36)
1 Collegium has one preclinical ADHD molecule
2 Based on Purdue internal projection
3 Based on Collegium 2018 Q3 10-Q 
• Given finite market 
outlook and Collegium’s 
need to quickly return to 
profitability, there are 2 
potential strategic 
choices:
– Reduce cost by 
downsizing salesforces, 
which could potentially 
lower expected sales 
growth
– Augment volume with 
aggressive bidding 
SOURCE: SEC filings, Internal research
-27 sales from PD “Perspective on global 
opioid and opiate markets” for narcotic 
products; 
7
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 20 Image 1 (OCR) ===
—

=== Page 20 Image 2 (OCR) ===
oe

=== Page 20 Image 3 (OCR) ===
a

=== Page 20 Image 4 (OCR) ===
Qunoue).

=== Page 20 Image 6 (OCR) ===
guaoue)

=== Page 20 Image 7 (OCR) ===
a

=== Page 20 Image 8 (OCR) ===
uaoue).

=== Page 20 Image 9 (OCR) ===
euaoue).

=== Page 20 Image 10 (OCR) ===
a

=== Page 20 Image 11 (OCR) ===
—

=== Page 20 Image 12 (OCR) ===
oe

=== Page 20 Image 13 (OCR) ===
a

=== Page 20 Image 14 (OCR) ===
Qunoue).

=== Page 20 Image 16 (OCR) ===
guaoue)

=== Page 20 Image 17 (OCR) ===
a

=== Page 20 Image 18 (OCR) ===
uaoue).

=== Page 20 Image 19 (OCR) ===
euaoue).

=== Page 20 Image 20 (OCR) ===
a

=== Page 20 Image 21 (OCR) ===
—

=== Page 20 Image 22 (OCR) ===
oe

=== Page 20 Image 23 (OCR) ===
a

=== Page 20 Image 24 (OCR) ===
Qunoue).

=== Page 20 Image 26 (OCR) ===
guaoue)

=== Page 20 Image 27 (OCR) ===
a

=== Page 20 Image 28 (OCR) ===
uaoue).

=== Page 20 Image 29 (OCR) ===
euaoue).

=== Page 20 Image 30 (OCR) ===
a

=== Page 20 Image 31 (OCR) ===
—

=== Page 20 Image 32 (OCR) ===
oe

=== Page 20 Image 33 (OCR) ===
a

=== Page 20 Image 34 (OCR) ===
Qunoue).

=== Page 20 Image 36 (OCR) ===
guaoue)

=== Page 20 Image 37 (OCR) ===
a

=== Page 20 Image 38 (OCR) ===
uaoue).

=== Page 20 Image 39 (OCR) ===
euaoue).

=== Page 20 Image 40 (OCR) ===
a

=== Page 20 Image 41 (OCR) ===
—

=== Page 20 Image 42 (OCR) ===
oe

=== Page 20 Image 43 (OCR) ===
a

=== Page 20 Image 44 (OCR) ===
Qunoue).

=== Page 20 Image 46 (OCR) ===
guaoue)

=== Page 20 Image 47 (OCR) ===
a

=== Page 20 Image 48 (OCR) ===
uaoue).

=== Page 20 Image 49 (OCR) ===
euaoue).

=== Page 20 Image 50 (OCR) ===
a

=== Page 20 Image 51 (OCR) ===
—

=== Page 20 Image 52 (OCR) ===
oe

=== Page 20 Image 53 (OCR) ===
a

=== Page 20 Image 54 (OCR) ===
Qunoue).

=== Page 20 Image 56 (OCR) ===
guaoue)

=== Page 20 Image 57 (OCR) ===
a

=== Page 20 Image 58 (OCR) ===
uaoue).

=== Page 20 Image 59 (OCR) ===
euaoue).

=== Page 20 Image 60 (OCR) ===
a

=== Page 20 Image 61 (OCR) ===
—

=== Page 20 Image 62 (OCR) ===
oe

=== Page 20 Image 63 (OCR) ===
a

=== Page 20 Image 64 (OCR) ===
Qunoue).

=== Page 20 Image 66 (OCR) ===
guaoue)

=== Page 20 Image 67 (OCR) ===
a

=== Page 20 Image 68 (OCR) ===
uaoue).

=== Page 20 Image 69 (OCR) ===
euaoue).

=== Page 20 Image 70 (OCR) ===
a

=== Page 21 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Current view of Collegium profitability
452
217
174
172
63
70
182
80
-32
Gross sales
Loss 
from 
operati
ons
Rebates
Other 
GTN 
reductio
ns
Net sales
9
COGS
R&D
SG&A
24
252
626
88
287
128
32
Xtampza
Nucynta
Overall 
Revenue and GTN 
reductions
Costs and operating 
expenses
2018 financial performance (estimation) 
($ Millions)
• Cash at the end of 
Q3 2018:  ~$140 
Mn
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 21 Image 1 (OCR) ===
—

=== Page 21 Image 2 (OCR) ===
oe

=== Page 21 Image 3 (OCR) ===
a

=== Page 21 Image 4 (OCR) ===
Qunoue).

=== Page 21 Image 6 (OCR) ===
guaoue)

=== Page 21 Image 7 (OCR) ===
a

=== Page 21 Image 8 (OCR) ===
uaoue).

=== Page 21 Image 9 (OCR) ===
euaoue).

=== Page 21 Image 10 (OCR) ===
a

=== Page 21 Image 11 (OCR) ===
—

=== Page 21 Image 12 (OCR) ===
oe

=== Page 21 Image 13 (OCR) ===
a

=== Page 21 Image 14 (OCR) ===
Qunoue).

=== Page 21 Image 16 (OCR) ===
guaoue)

=== Page 21 Image 17 (OCR) ===
a

=== Page 21 Image 18 (OCR) ===
uaoue).

=== Page 21 Image 19 (OCR) ===
euaoue).

=== Page 21 Image 20 (OCR) ===
a

=== Page 21 Image 21 (OCR) ===
—

=== Page 21 Image 22 (OCR) ===
oe

=== Page 21 Image 23 (OCR) ===
a

=== Page 21 Image 24 (OCR) ===
Qunoue).

=== Page 21 Image 26 (OCR) ===
guaoue)

=== Page 21 Image 27 (OCR) ===
a

=== Page 21 Image 28 (OCR) ===
uaoue).

=== Page 21 Image 29 (OCR) ===
euaoue).

=== Page 21 Image 30 (OCR) ===
a

=== Page 21 Image 31 (OCR) ===
—

=== Page 21 Image 32 (OCR) ===
oe

=== Page 21 Image 33 (OCR) ===
a

=== Page 21 Image 34 (OCR) ===
Qunoue).

=== Page 21 Image 36 (OCR) ===
guaoue)

=== Page 21 Image 37 (OCR) ===
a

=== Page 21 Image 38 (OCR) ===
uaoue).

=== Page 21 Image 39 (OCR) ===
euaoue).

=== Page 21 Image 40 (OCR) ===
a

=== Page 21 Image 41 (OCR) ===
—

=== Page 21 Image 42 (OCR) ===
oe

=== Page 21 Image 43 (OCR) ===
a

=== Page 21 Image 44 (OCR) ===
Qunoue).

=== Page 21 Image 46 (OCR) ===
guaoue)

=== Page 21 Image 47 (OCR) ===
a

=== Page 21 Image 48 (OCR) ===
uaoue).

=== Page 21 Image 49 (OCR) ===
euaoue).

=== Page 21 Image 50 (OCR) ===
a

=== Page 21 Image 51 (OCR) ===
—

=== Page 21 Image 52 (OCR) ===
oe

=== Page 21 Image 53 (OCR) ===
a

=== Page 21 Image 54 (OCR) ===
Qunoue).

=== Page 21 Image 56 (OCR) ===
guaoue)

=== Page 21 Image 57 (OCR) ===
a

=== Page 21 Image 58 (OCR) ===
uaoue).

=== Page 21 Image 59 (OCR) ===
euaoue).

=== Page 21 Image 60 (OCR) ===
a

=== Page 21 Image 61 (OCR) ===
—

=== Page 21 Image 62 (OCR) ===
oe

=== Page 21 Image 63 (OCR) ===
a

=== Page 21 Image 64 (OCR) ===
Qunoue).

=== Page 21 Image 66 (OCR) ===
guaoue)

=== Page 21 Image 67 (OCR) ===
a

=== Page 21 Image 68 (OCR) ===
uaoue).

=== Page 21 Image 69 (OCR) ===
euaoue).

=== Page 21 Image 70 (OCR) ===
a

=== Page 22 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Collegium would need to double current share of Xtampza in order to break even
9
Potential impact of doubling Xtampza share through exclusive contracts with additional payors
14
Current loss 
from 
operations
2020 
operating 
income
Loss due to 
market 
decline
Growth from 
existing 
account
Growth 
from new 
account
COGS increase
0
32
19
15
50
Key 
assumptions:
• ERO market 
continues to 
decline at -15% 
year on year 
until 2020
• GtN of sales with 
new account: 
60%
• Nucynta sales 
remains the 
same
• SG&A remains 
the same
Projected 2020 Xtampza  financial performance 
($ Millions)
DIRECTIONAL ESTIMATION
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 22 Image 1 (OCR) ===
—

=== Page 22 Image 2 (OCR) ===
oe

=== Page 22 Image 3 (OCR) ===
a

=== Page 22 Image 4 (OCR) ===
Qunoue).

=== Page 22 Image 6 (OCR) ===
guaoue)

=== Page 22 Image 7 (OCR) ===
a

=== Page 22 Image 8 (OCR) ===
uaoue).

=== Page 22 Image 9 (OCR) ===
euaoue).

=== Page 22 Image 10 (OCR) ===
a

=== Page 22 Image 11 (OCR) ===
—

=== Page 22 Image 12 (OCR) ===
oe

=== Page 22 Image 13 (OCR) ===
a

=== Page 22 Image 14 (OCR) ===
Qunoue).

=== Page 22 Image 16 (OCR) ===
guaoue)

=== Page 22 Image 17 (OCR) ===
a

=== Page 22 Image 18 (OCR) ===
uaoue).

=== Page 22 Image 19 (OCR) ===
euaoue).

=== Page 22 Image 20 (OCR) ===
a

=== Page 22 Image 21 (OCR) ===
—

=== Page 22 Image 22 (OCR) ===
oe

=== Page 22 Image 23 (OCR) ===
a

=== Page 22 Image 24 (OCR) ===
Qunoue).

=== Page 22 Image 26 (OCR) ===
guaoue)

=== Page 22 Image 27 (OCR) ===
a

=== Page 22 Image 28 (OCR) ===
uaoue).

=== Page 22 Image 29 (OCR) ===
euaoue).

=== Page 22 Image 30 (OCR) ===
a

=== Page 22 Image 31 (OCR) ===
—

=== Page 22 Image 32 (OCR) ===
oe

=== Page 22 Image 33 (OCR) ===
a

=== Page 22 Image 34 (OCR) ===
Qunoue).

=== Page 22 Image 36 (OCR) ===
guaoue)

=== Page 22 Image 37 (OCR) ===
a

=== Page 22 Image 38 (OCR) ===
uaoue).

=== Page 22 Image 39 (OCR) ===
euaoue).

=== Page 22 Image 40 (OCR) ===
a

=== Page 22 Image 41 (OCR) ===
—

=== Page 22 Image 42 (OCR) ===
oe

=== Page 22 Image 43 (OCR) ===
a

=== Page 22 Image 44 (OCR) ===
Qunoue).

=== Page 22 Image 46 (OCR) ===
guaoue)

=== Page 22 Image 47 (OCR) ===
a

=== Page 22 Image 48 (OCR) ===
uaoue).

=== Page 22 Image 49 (OCR) ===
euaoue).

=== Page 22 Image 50 (OCR) ===
a

=== Page 22 Image 51 (OCR) ===
—

=== Page 22 Image 52 (OCR) ===
oe

=== Page 22 Image 53 (OCR) ===
a

=== Page 22 Image 54 (OCR) ===
Qunoue).

=== Page 22 Image 56 (OCR) ===
guaoue)

=== Page 22 Image 57 (OCR) ===
a

=== Page 22 Image 58 (OCR) ===
uaoue).

=== Page 22 Image 59 (OCR) ===
euaoue).

=== Page 22 Image 60 (OCR) ===
a

=== Page 22 Image 61 (OCR) ===
—

=== Page 22 Image 62 (OCR) ===
oe

=== Page 22 Image 63 (OCR) ===
a

=== Page 22 Image 64 (OCR) ===
Qunoue).

=== Page 22 Image 66 (OCR) ===
guaoue)

=== Page 22 Image 67 (OCR) ===
a

=== Page 22 Image 68 (OCR) ===
uaoue).

=== Page 22 Image 69 (OCR) ===
euaoue).

=== Page 22 Image 70 (OCR) ===
a

=== Page 23 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Overview of top accounts across Commercial and Medicare: current view
10
Net sales1
$M
Market 
segment
Commer-
cial
11%
7%
6%
2%
2%
1%
1%
1%
1%
1%
11%
5%
2%
1%
1%
0%
54%
21%
17%
13%
21%
23%
20%
4%
9%
3%
5%
26%
14%
14%
15%
17%
14%
42%
35%
38%
21%
28%
29%
0%
20%
0%
0%
56%
66%
38%
40%
37%
28%
112
992
193
21
102
26
21
7
12
11
6
258
155
26
20
8
5
10
73
17
18
113
63
15
9
6
6
113
13
17
53
5
4
545
2019 contracting
Medicare 
Part D
Current status (FYE June 2018)
1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; 
3 Assuming status carries over from 201807 period for those accounts with OxyContin formulary access, status based on majority of lives; 4 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other 
prime accounts 
Account
Express Scripts
Caremark
OptumRx  - United Healthcare
Aetna Health Plans
Prime Therapeutics - excl HCSC4
Prime Therapeutics - HCSC
Cigna Healthcare
Procare
BCBS FL (Prime Therapeutics)
Independence BCBS (PA)
Caremark
OptumRx  - United Healthcare
Express Scripts
Prime Therapeutics
EnvisionRx Options
Total
Gross sales
$M 
Market 
Share
% 
Net sales 
OxyContin
2T Preferred
NOF
NOF
2T Preferred
NOF
3T Preferred
3T Pref PDP/MAPD NOF
Pref MAPD/PDP NOF
2T Preferred
2T Preferred
2T Preferred 
2T Preferred
2T Preferred
2T Preferred
NOF
MedImpact
2T Preferred
Rebate2
Xtampza ER3
Non-preferred
Preferred
Preferred
Non-preferred
Preferred
NOF
Preferred
NOF
NOF
NOF
Non-preferred
Non-preferred
Preferred
Non-preferred
Preferred
Preferred
2019 formulary status
Collegium is 
likely to 
double 
down on big 
national 
accounts in 
order to 
achieve 
break-even
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 23 Image 1 (OCR) ===
—

=== Page 23 Image 2 (OCR) ===
oe

=== Page 23 Image 3 (OCR) ===
a

=== Page 23 Image 4 (OCR) ===
Qunoue).

=== Page 23 Image 6 (OCR) ===
guaoue)

=== Page 23 Image 7 (OCR) ===
a

=== Page 23 Image 8 (OCR) ===
uaoue).

=== Page 23 Image 9 (OCR) ===
euaoue).

=== Page 23 Image 10 (OCR) ===
a

=== Page 23 Image 11 (OCR) ===
—

=== Page 23 Image 12 (OCR) ===
oe

=== Page 23 Image 13 (OCR) ===
a

=== Page 23 Image 14 (OCR) ===
Qunoue).

=== Page 23 Image 16 (OCR) ===
guaoue)

=== Page 23 Image 17 (OCR) ===
a

=== Page 23 Image 18 (OCR) ===
uaoue).

=== Page 23 Image 19 (OCR) ===
euaoue).

=== Page 23 Image 20 (OCR) ===
a

=== Page 23 Image 21 (OCR) ===
—

=== Page 23 Image 22 (OCR) ===
oe

=== Page 23 Image 23 (OCR) ===
a

=== Page 23 Image 24 (OCR) ===
Qunoue).

=== Page 23 Image 26 (OCR) ===
guaoue)

=== Page 23 Image 27 (OCR) ===
a

=== Page 23 Image 28 (OCR) ===
uaoue).

=== Page 23 Image 29 (OCR) ===
euaoue).

=== Page 23 Image 30 (OCR) ===
a

=== Page 23 Image 31 (OCR) ===
—

=== Page 23 Image 32 (OCR) ===
oe

=== Page 23 Image 33 (OCR) ===
a

=== Page 23 Image 34 (OCR) ===
Qunoue).

=== Page 23 Image 36 (OCR) ===
guaoue)

=== Page 23 Image 37 (OCR) ===
a

=== Page 23 Image 38 (OCR) ===
uaoue).

=== Page 23 Image 39 (OCR) ===
euaoue).

=== Page 23 Image 40 (OCR) ===
a

=== Page 23 Image 41 (OCR) ===
—

=== Page 23 Image 42 (OCR) ===
oe

=== Page 23 Image 43 (OCR) ===
a

=== Page 23 Image 44 (OCR) ===
Qunoue).

=== Page 23 Image 46 (OCR) ===
guaoue)

=== Page 23 Image 47 (OCR) ===
a

=== Page 23 Image 48 (OCR) ===
uaoue).

=== Page 23 Image 49 (OCR) ===
euaoue).

=== Page 23 Image 50 (OCR) ===
a

=== Page 23 Image 51 (OCR) ===
—

=== Page 23 Image 52 (OCR) ===
oe

=== Page 23 Image 53 (OCR) ===
a

=== Page 23 Image 54 (OCR) ===
Qunoue).

=== Page 23 Image 56 (OCR) ===
guaoue)

=== Page 23 Image 57 (OCR) ===
a

=== Page 23 Image 58 (OCR) ===
uaoue).

=== Page 23 Image 59 (OCR) ===
euaoue).

=== Page 23 Image 60 (OCR) ===
a

=== Page 23 Image 61 (OCR) ===
—

=== Page 23 Image 62 (OCR) ===
oe

=== Page 23 Image 63 (OCR) ===
a

=== Page 23 Image 64 (OCR) ===
Qunoue).

=== Page 23 Image 66 (OCR) ===
guaoue)

=== Page 23 Image 67 (OCR) ===
a

=== Page 23 Image 68 (OCR) ===
uaoue).

=== Page 23 Image 69 (OCR) ===
euaoue).

=== Page 23 Image 70 (OCR) ===
a

=== Page 24 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
Current access status: OxyContin is preferred for 47% of lives on Prime’s Part D formularies
11
SOURCE: MMIT
• OxyContin is the preferred oxycodone with access to nearly half of Prime lives while Xtampza ER is excluded
• Zohydro ER is the preferred branded hydrocodone product (Hysingla ER is completely excluded), and Nucynta also maintains access 
to half of Prime lives
531
94
8
26
575
25552
Privileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal 
and regulatory review before they can be considered final. These materials are confidential and proprietary.
1 Includes ~10K lives where no PA/ST required for OxyContin and Nucynta
2 Defined as percentage of lives that are either preferred or covered (including PA/ST)
Lives, K
Overall formulary 
status
Lives, 
%
Hysingl
a ER
Xtampz
a ER
OxyCo
ntin
Nucynt
a ER
Zohydr
o ER
1,235
Overall covered 
lives %2
0%
0%
47%
47%
92%
Largest formulary
47
%
Collegium 
excluded1 
Not 
Covered
Not 
Covered
Preferre
d 
(PA/ST)
Preferred 
(PA/ST)
Covered 
(PA/ST)
BCBS FL BlueMedicare Classic 
and Choice 
43%
Only Zohydro - 
covered
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Covered 
(PA/ST) 
HISC Blue Medicare Rx (PDP) 
Plus and Value 
8%
No branded ERO 
coverage
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Regence BCBS of Oregon 
MedAdvantage + RxClassic PPO 
+ RxEnhanced PPO 
2%
Only Zohydro - 
preferred
Not 
Covered
Not 
Covered
Not 
Covered
Not 
Covered
Preferred 
(PA/ST)
Blue Cross Community MMAI 
1
%
OxyContin and 
Zohydro 
preferred
Not 
Covered
Not 
Covered
Preferre
d 
(PA/ST)
Not 
Covered
Preferred 
(PA/ST)
Blue Cross Blue Shield of 
Minnesota SecureBlue 
Coverage status of leading ERO brands, 
Nov 2018
PRIME
Total
Oxycontin Covered
Not covered
11
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 24 Image 1 (OCR) ===
—

=== Page 24 Image 2 (OCR) ===
oe

=== Page 24 Image 3 (OCR) ===
a

=== Page 24 Image 4 (OCR) ===
Qunoue).

=== Page 24 Image 6 (OCR) ===
guaoue)

=== Page 24 Image 7 (OCR) ===
a

=== Page 24 Image 8 (OCR) ===
uaoue).

=== Page 24 Image 9 (OCR) ===
euaoue).

=== Page 24 Image 10 (OCR) ===
a

=== Page 24 Image 11 (OCR) ===
—

=== Page 24 Image 12 (OCR) ===
oe

=== Page 24 Image 13 (OCR) ===
a

=== Page 24 Image 14 (OCR) ===
Qunoue).

=== Page 24 Image 16 (OCR) ===
guaoue)

=== Page 24 Image 17 (OCR) ===
a

=== Page 24 Image 18 (OCR) ===
uaoue).

=== Page 24 Image 19 (OCR) ===
euaoue).

=== Page 24 Image 20 (OCR) ===
a

=== Page 24 Image 21 (OCR) ===
—

=== Page 24 Image 22 (OCR) ===
oe

=== Page 24 Image 23 (OCR) ===
a

=== Page 24 Image 24 (OCR) ===
Qunoue).

=== Page 24 Image 26 (OCR) ===
guaoue)

=== Page 24 Image 27 (OCR) ===
a

=== Page 24 Image 28 (OCR) ===
uaoue).

=== Page 24 Image 29 (OCR) ===
euaoue).

=== Page 24 Image 30 (OCR) ===
a

=== Page 24 Image 31 (OCR) ===
—

=== Page 24 Image 32 (OCR) ===
oe

=== Page 24 Image 33 (OCR) ===
a

=== Page 24 Image 34 (OCR) ===
Qunoue).

=== Page 24 Image 36 (OCR) ===
guaoue)

=== Page 24 Image 37 (OCR) ===
a

=== Page 24 Image 38 (OCR) ===
uaoue).

=== Page 24 Image 39 (OCR) ===
euaoue).

=== Page 24 Image 40 (OCR) ===
a

=== Page 24 Image 41 (OCR) ===
—

=== Page 24 Image 42 (OCR) ===
oe

=== Page 24 Image 43 (OCR) ===
a

=== Page 24 Image 44 (OCR) ===
Qunoue).

=== Page 24 Image 46 (OCR) ===
guaoue)

=== Page 24 Image 47 (OCR) ===
a

=== Page 24 Image 48 (OCR) ===
uaoue).

=== Page 24 Image 49 (OCR) ===
euaoue).

=== Page 24 Image 50 (OCR) ===
a

=== Page 24 Image 51 (OCR) ===
—

=== Page 24 Image 52 (OCR) ===
oe

=== Page 24 Image 53 (OCR) ===
a

=== Page 24 Image 54 (OCR) ===
Qunoue).

=== Page 24 Image 56 (OCR) ===
guaoue)

=== Page 24 Image 57 (OCR) ===
a

=== Page 24 Image 58 (OCR) ===
uaoue).

=== Page 24 Image 59 (OCR) ===
euaoue).

=== Page 24 Image 60 (OCR) ===
a

=== Page 24 Image 61 (OCR) ===
—

=== Page 24 Image 62 (OCR) ===
oe

=== Page 24 Image 63 (OCR) ===
a

=== Page 24 Image 64 (OCR) ===
Qunoue).

=== Page 24 Image 66 (OCR) ===
guaoue)

=== Page 24 Image 67 (OCR) ===
a

=== Page 24 Image 68 (OCR) ===
uaoue).

=== Page 24 Image 69 (OCR) ===
euaoue).

=== Page 24 Image 70 (OCR) ===
a

=== Page 25 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We defined potential 2020 access scenarios for Oxycontin vs. Xtampza
2020 Share shift assumptions under different scenarios, 2020 Q4 
2020 access 
scenarios
Continue current 
access status as 
exclusive preferred 
oxycodone ER
1
1
1
2
3
15
7
14
4
4
10
4
4
10
6
5
5
6
7
5
8
4
Oxycontin
Other 
Xtampza
Share by products (exit share) 
Share shift vs. 
status quo 
Xtampza covered 
(non-preferred), 
while OxyContin 
stays preferred
2
Low
Hig
h
5%
35%
Xtampza replaces 
Oxycontin as 
exclusive preferred 
with 
grandfathering
3
Low
Hig
h
35%
55%
Oxycontin Excluded 
without 
grandfathering
4
Low
Hig
h
50%
70%
0%
ENVISION
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 25 Image 1 (OCR) ===
—

=== Page 25 Image 2 (OCR) ===
oe

=== Page 25 Image 3 (OCR) ===
a

=== Page 25 Image 4 (OCR) ===
Qunoue).

=== Page 25 Image 6 (OCR) ===
guaoue)

=== Page 25 Image 7 (OCR) ===
a

=== Page 25 Image 8 (OCR) ===
uaoue).

=== Page 25 Image 9 (OCR) ===
euaoue).

=== Page 25 Image 10 (OCR) ===
a

=== Page 25 Image 11 (OCR) ===
—

=== Page 25 Image 12 (OCR) ===
oe

=== Page 25 Image 13 (OCR) ===
a

=== Page 25 Image 14 (OCR) ===
Qunoue).

=== Page 25 Image 16 (OCR) ===
guaoue)

=== Page 25 Image 17 (OCR) ===
a

=== Page 25 Image 18 (OCR) ===
uaoue).

=== Page 25 Image 19 (OCR) ===
euaoue).

=== Page 25 Image 20 (OCR) ===
a

=== Page 25 Image 21 (OCR) ===
—

=== Page 25 Image 22 (OCR) ===
oe

=== Page 25 Image 23 (OCR) ===
a

=== Page 25 Image 24 (OCR) ===
Qunoue).

=== Page 25 Image 26 (OCR) ===
guaoue)

=== Page 25 Image 27 (OCR) ===
a

=== Page 25 Image 28 (OCR) ===
uaoue).

=== Page 25 Image 29 (OCR) ===
euaoue).

=== Page 25 Image 30 (OCR) ===
a

=== Page 25 Image 31 (OCR) ===
—

=== Page 25 Image 32 (OCR) ===
oe

=== Page 25 Image 33 (OCR) ===
a

=== Page 25 Image 34 (OCR) ===
Qunoue).

=== Page 25 Image 36 (OCR) ===
guaoue)

=== Page 25 Image 37 (OCR) ===
a

=== Page 25 Image 38 (OCR) ===
uaoue).

=== Page 25 Image 39 (OCR) ===
euaoue).

=== Page 25 Image 40 (OCR) ===
a

=== Page 25 Image 41 (OCR) ===
—

=== Page 25 Image 42 (OCR) ===
oe

=== Page 25 Image 43 (OCR) ===
a

=== Page 25 Image 44 (OCR) ===
Qunoue).

=== Page 25 Image 46 (OCR) ===
guaoue)

=== Page 25 Image 47 (OCR) ===
a

=== Page 25 Image 48 (OCR) ===
uaoue).

=== Page 25 Image 49 (OCR) ===
euaoue).

=== Page 25 Image 50 (OCR) ===
a

=== Page 25 Image 51 (OCR) ===
—

=== Page 25 Image 52 (OCR) ===
oe

=== Page 25 Image 53 (OCR) ===
a

=== Page 25 Image 54 (OCR) ===
Qunoue).

=== Page 25 Image 56 (OCR) ===
guaoue)

=== Page 25 Image 57 (OCR) ===
a

=== Page 25 Image 58 (OCR) ===
uaoue).

=== Page 25 Image 59 (OCR) ===
euaoue).

=== Page 25 Image 60 (OCR) ===
a

=== Page 25 Image 61 (OCR) ===
—

=== Page 25 Image 62 (OCR) ===
oe

=== Page 25 Image 63 (OCR) ===
a

=== Page 25 Image 64 (OCR) ===
Qunoue).

=== Page 25 Image 66 (OCR) ===
guaoue)

=== Page 25 Image 67 (OCR) ===
a

=== Page 25 Image 68 (OCR) ===
uaoue).

=== Page 25 Image 69 (OCR) ===
euaoue).

=== Page 25 Image 70 (OCR) ===
a

=== Page 26 ===
PROPRIETARY AND 
CONFIDENTIAL
PROPRIETARY AND 
CONFIDENTIAL
We modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios
1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”
2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering 
5.9
6.8
6.8
6.2
4.9
5.8
4.8
4.4
Access 
scenarios tested
Xtampza 
covered (non-
preferred), 
while 
OxyContin 
stays 
preferred
Continue 
current 
access status 
as exclusive 
preferred 
oxycodone ER
Xtampza 
replaces 
Oxycontin as 
exclusive 
preferred with 
grandfatherin
gOxycontin 
Excluded 
without 
grandfatherin
g
Xtampza net 
sales ($M)
1
2
3
0%
50%
70%
70%
Assumed 
Xtampza 
rebate
Implication on Oxycontin bidding strategy
 to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. 
0.5
0.2
0.7
0.4
0.5
0.7
Share by 
product
Other brand 
net sales 
($M)
4
5
3
4
1
14
4
4
10
4
10
5
6
7
7
5
6
8
4
18
18
18
18
18
17
2.1
1.4
1.9
1.9
2.2
2.4
Oxycontin
Xtampza
Other brands
Sha
re 
shif
t
Low
Hig
h
Low
Hig
h
Low
Hig
h
Low
Hig
h
ENVISION
15
2
1 18
0.7
0.8
46%
Break-
even 
rebate2 
31%
35%
N/A
13%
33%
Net sales at min 
rebate ($M)
Rebate rate to keep 
Envision whole1 
32%
22%
29%
N/A
8%
10%
24%
Theoretic
al – 
unlikely 
able to 
lower 
current 
rate 
(40%)
16%
13
Source:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257

=== Page 26 Image 1 (OCR) ===
—

=== Page 26 Image 2 (OCR) ===
oe

=== Page 26 Image 3 (OCR) ===
a

=== Page 26 Image 4 (OCR) ===
Qunoue).

=== Page 26 Image 6 (OCR) ===
guaoue)

=== Page 26 Image 7 (OCR) ===
a

=== Page 26 Image 8 (OCR) ===
uaoue).

=== Page 26 Image 9 (OCR) ===
euaoue).

=== Page 26 Image 10 (OCR) ===
a

=== Page 26 Image 11 (OCR) ===
—

=== Page 26 Image 12 (OCR) ===
oe

=== Page 26 Image 13 (OCR) ===
a

=== Page 26 Image 14 (OCR) ===
Qunoue).

=== Page 26 Image 16 (OCR) ===
guaoue)

=== Page 26 Image 17 (OCR) ===
a

=== Page 26 Image 18 (OCR) ===
uaoue).

=== Page 26 Image 19 (OCR) ===
euaoue).

=== Page 26 Image 20 (OCR) ===
a

=== Page 26 Image 21 (OCR) ===
—

=== Page 26 Image 22 (OCR) ===
oe

=== Page 26 Image 23 (OCR) ===
a

=== Page 26 Image 24 (OCR) ===
Qunoue).

=== Page 26 Image 26 (OCR) ===
guaoue)

=== Page 26 Image 27 (OCR) ===
a

=== Page 26 Image 28 (OCR) ===
uaoue).

=== Page 26 Image 29 (OCR) ===
euaoue).

=== Page 26 Image 30 (OCR) ===
a

=== Page 26 Image 31 (OCR) ===
—

=== Page 26 Image 32 (OCR) ===
oe

=== Page 26 Image 33 (OCR) ===
a

=== Page 26 Image 34 (OCR) ===
Qunoue).

=== Page 26 Image 36 (OCR) ===
guaoue)

=== Page 26 Image 37 (OCR) ===
a

=== Page 26 Image 38 (OCR) ===
uaoue).

=== Page 26 Image 39 (OCR) ===
euaoue).

=== Page 26 Image 40 (OCR) ===
a

=== Page 26 Image 41 (OCR) ===
—

=== Page 26 Image 42 (OCR) ===
oe

=== Page 26 Image 43 (OCR) ===
a

=== Page 26 Image 44 (OCR) ===
Qunoue).

=== Page 26 Image 46 (OCR) ===
guaoue)

=== Page 26 Image 47 (OCR) ===
a

=== Page 26 Image 48 (OCR) ===
uaoue).

=== Page 26 Image 49 (OCR) ===
euaoue).

=== Page 26 Image 50 (OCR) ===
a

=== Page 26 Image 51 (OCR) ===
—

=== Page 26 Image 52 (OCR) ===
oe

=== Page 26 Image 53 (OCR) ===
a

=== Page 26 Image 54 (OCR) ===
Qunoue).

=== Page 26 Image 56 (OCR) ===
guaoue)

=== Page 26 Image 57 (OCR) ===
a

=== Page 26 Image 58 (OCR) ===
uaoue).

=== Page 26 Image 59 (OCR) ===
euaoue).

=== Page 26 Image 60 (OCR) ===
a

=== Page 26 Image 61 (OCR) ===
—

=== Page 26 Image 62 (OCR) ===
oe

=== Page 26 Image 63 (OCR) ===
a

=== Page 26 Image 64 (OCR) ===
Qunoue).

=== Page 26 Image 66 (OCR) ===
guaoue)

=== Page 26 Image 67 (OCR) ===
a

=== Page 26 Image 68 (OCR) ===
uaoue).

=== Page 26 Image 69 (OCR) ===
euaoue).

=== Page 26 Image 70 (OCR) ===
a